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Abstract
Protein disulfide isomerase (PDI) is a multifunctional protein most well char
acterized for its ability to form and exchange disulfide bonds (Darby et al., 1996).
More recently, a host of other functions have been added to the resume of this protein,
including denitrosation activity (Zai et al., 1999), mediation of integrin-dependent
adhesion (Lahav et al., 2000), and copper binding activity (Narindrasorasak et al,
2003). PDI is a 110 kDa homodimer and contains five domains, a-b-b’-a ’c (Darby et
al, 1996). The a and a ’ domains contain the Cys-Gly-His-Cys active site residues
responsible for the thiol-disulfide exchange reactions (Darby et al., 1996). Although
this protein is predominantly localized within the endoplasmic reticulum depending
on the cell type, PDI has also been found in secretory vesicles, the Golgi, and the
plasma membrane (Akagi et al., 1988) of eukaryotic cells. In glial astrocytes, PDI
is also found throughout the cytosol (Safran and Leonard, 1991), but its interaction
between the cytoplasm and endoplasmic reticulum is not fully understood. Under is
chemic stress, PDI is upregulated in rat forebrain cells, suggesting protection against
cellular stresses (Tanaka et al, 1999). The localization of PDI in differentiated human
neuroblastoma SH-SY5Y cells was probed by the development of a recombinant fusion
protein between green fluorescent protein GFP and PDI. SH-SY5Y cells expressing
the recombinant reporter protein were also exposed to oxidative and ischemic stress,
and examined for characteristics of apoptosis. These cells demonstrated that PDI
provides a significant decrease in apoptotic traits as compared to the control cells.
It was observed that there was reduced nuclear condensation, and maintainence of
mitochondrial membrane potential. Cells containing the recombinant protein also
showed an increased number of viable cells when exposed to hypoxic stress. These
results suggest that PDI plays a role in the protective mechanism towards cellular
stress. Excessive neuronal loss induced by oxidative stress is often seen in patients
due to aging, strokes, and neurodegenerative diseases. The results obtained by using
this cell line for the study of neuronal cell death have potential implication for strokes
and human neurodegenerative diseases.
iii
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Chapter 1
General Introduction
1.1

P rotein Disulfide Isomerase
There are a m ultitude of events th a t occur in the endoplasmic reticulum (ER) of

the cell such as lipid biosynthesis, calcium storage, and most notably protein synthesis
and modification.

The ER is composed of a system of membranes th a t extends

throughout the cytosol, and connects to the nuclear envelope. W ithin this dynamic
network, lies a powerhouse of a protein, and with every new experiment another title
is added to its host of newly discovered functions and activities. Protein disulfide
isomerase (PDI), is most widely known for its role in protein folding and disulfide
bond isomerization. Before PDI was classified, early work on the protein described
an enzyme able to catalyze thiol exchange reactions in protein folding (Goldberger
et al, 1964).

Folding in vitro can take minutes to hours for disulfide formation

to take place. In the 1964 paper by Goldberger and colleagues, the “microsomal
protein” had a specific activity 88 times th a t of th e “microsome” alone. There is
a high concentration of PDI found in the ER - approxim ately 0.2 mM (Lyles and
Gilbert, 1991). Also, PD I has a low affinity interacting with its substrates. This
lack of substrate specificity would be consistent with its ability to isomerize disulfide
bonds in a myriad of different proteins.

1
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1.1.1

P D I Structure

M amm alian PDI is approximately 57 000 Da, and is made of approximately
491 amino acid residues (Darby and Creighton, 1998). The length of the protein
can be debatable depending on the inclusion of a leader peptide signal. Throughout
this thesis, the hum an PDI sequence obtained from the cDNA from pET-1 la will be
used (Appendix A). This sequence matches the human PD I sequence patented by
Kato and coworkers in 1991, with the removal of the beginning 20 amino acid signal
sequence. S tructural analysis of the 120 residue a domain (Kemmink, et al., 1996),
and 110 residue b domain (Kemmink, et al., 1999) of hum an PD I places it in the
thioredoxin superfamily (SCOP 52833, CATH 3.40.30.10)(Murzin et al., 1995, Pearl
et al., 2005). An NMR structure of the full length protein has not yet been eluci
dated. The characteristic sequence Cys-Gly-His-Cys found in the active site domains
of the protein bear high sequence and structural homology to another redox protein,
thioredoxin, which is found in both prokaryotic and eukaryotic cells. The members
of this superfamily share the vicinal thiols, but differ in the two amino acids found
between, which can directly affect the catalytic activity of the protein (see section
1.1.2 Thioredoxin). The structure of mammalian PDI has been classified into five
different domains; a, b, b’, a, and c (figure 1.1) (Kemmink et al., 1996). Although
PDI is found predom inantly in the ER, PDI has been identified as subunits of other
proteins including prolyl-4-hydroxylase, an enzyme involved in post-translational hydroxylation of peptidyl proline residues, and microsomal triglyceride transfer protein
complex (M TP), a protein th a t transports triglyceride and cholesterol esters across
membranes (W etterau et al., 1991). PDI has been found to have sequence homology
with other proteins of unrelated function. For example, the b domain contains se
quence homology to calsequesterin, a protein which pools calcium in the sarcoplasmic
reticulum of muscle cells (Noiva, 1999). Located in the c-domain are acidic residues
thought to bind calcium, which suggests th a t PDI has calcium storage and buffering
capacity (C orbett et al., 1999).

2

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CGHC

36

CGHC

39

384

KDEL

387

Figure 1.1: The structural domains of mammalian PDI. Kemmink and coworkers
(1996) proposed this model of the structural domains of PDI. The location of the
active site cysteines are found in the a and a ’ domains. The b and b ’ domains are
responsible for chaperonic activity, and the c domain contains the carboxyl-terminal
KDEL ER retention signal. The residue numbering is consistent with the sequence
found in Appendix A.

3
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The activities of isolated a and a ’domains are capable of catalyzing disulfide bond
isomerization, b u t are less efficient than the entire PD I protein (Darby and Creighton,
1995), giving further proof for the im portance of the other domains in the protein.
The b ’ domain of PD I can bind unstructured regions of polypeptide to assist in
the folding process (Freedman et al., 2002). The im portance of the b ’ domain to
the chaperonic activity of PD I was dem onstrated in a 2004 paper by Horibe and
coworkers. By replacing the b domain in hum an protein disulfide isomerase related
protein (hPDIR) with the b ’ domain from human PDI, the chaperonic activity of the
protein was found to increase. The c domain has also been shown to help stabilize the
chaperone function of the protein (Tian et al., 2004). Also contained in the c domain
is the KDEL sequence which is characteristic of controlling ER retention. Figure 1.2
shows the NMR structures of the a (left) and b (right) domains of PDI. Notice the
two active site cysteines depicted in ball and stick imagery.

4
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Figure 1.2: Domains a and b of human PD I from www.pdb.org (Berman et al.,
2000) (Date accessed 04/05/05). Figure (A) shows only one of 40 NMR structures of
isolated hum an PD I a (A) domain. The active site cysteines are shown in ball and
stick representation, located at residues 36 and 39. Figure (B) shows only one of 24
NMR structures of hum an PDI b (B) domain. Although not responsible for catalytic
action, it is im portant for substrate stabilization. Accession number for the a domain
is 1MEK, and b domain is 2BJX. The interactive Rasmol display was saved for each
file, and structure modelling was done in Rasmol v.2.7.2.1.1.

5
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1.1.2

T hioredoxin

The thioredoxin (TRX) superfamily (SCOP 52833, CATH 3.40.30.10) consists of
a group of proteins responsible for disulfide bond formation. The bacterial proteins
include the Dsb (disulfide bond) and thioredoxin proteins. The bacterial disulfide
bond (Dsb) proteins share the vicinal Cys residues in their active site (Table 1.1).
The catalytic efficiency of the proteins are directed by the amino acids found between
the two cysteines (R aina and Missiakas, 1997). Mutagenesis of the His-38 residue of
PDI to Pro, makes this tetrapeptide sequence identical to thioredoxin, b u t results
in a decrease in PD I activity (Lu et al., 1992). The active site in the a domain
(PDIa) is located between b eta sheet three and alpha helix four - as shown in figure
1.2. B oth the a and a ’ domains are highly homologous to T R X protein of bacterial
cells.

A common feature shared with thioredoxin is the a lp h a/b eta fold of the a

domain w ith the structure of /3a/3al3(3a (Freedman et al., 2002). The most notable
difference between these proteins is th a t TRX exists in the periplasm of bacterial
cells and catalyzes reductive reactions suitable to the reducing environment of the
cells, whereas PD I exists predominantly within the less reducing ER, catalyzing both
oxidative and reductive reactions.

6
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DsbA

C

DsbB

C V L

C

E. coli

DsbC

c
c
c
c
c

c
c
c
c
c

E. coli

DsbD
DsbE
Thioredoxin
PDI-a

p

H C

G Y
V A
P

T

G P
G H

E. coli

E. coli
E. coli
E. coli
H. sapiens

Table 1.1: Members of the Thioredoxin Superfamily. A comparison of the active sites
of 5 E. coli Dsb proteins, thioredoxin, and human PD I (R aina and Missiakas, 1997).
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1.1.3

P D I D isulfide B ond R earrangem ent

The enzym atic goal of PDI is to replace reactive disulfides of its substrate with
less reactive ones. This is based on a trial and error process, in which three different
types of reactions take place: isomerization, reduction, and oxidation. This begins
with PD I forming a complex with the misfolded substrate, so th a t one of the disul
fides is disrupted to create a free sulfhydryl in the substrate. From the intermediate
formed, the reaction can proceed in three different directions (Gilbert, 1997). The
enzyme can be displaced, and the same disulfide bond will re-form so th a t no re
arrangem ent occurs. The second reaction th a t can occur involves an intermolecular
reaction between another substrate disulfide with the substrate thiol, to form a newly
folded protein. Lastly, the substrate can be reduced to the original disulfide and then
oxidized to form a different disulfide. In the last process, the second cysteine in the
active site of PD I acts like a timer in th a t it induces reduction of the substrate, if
a complex does not rearrange within a certain time. In the pink pathway of figure
1.3, simple rearrangem ent of substrate disulfides takes place. In the blue pathway
of figure 1.3, it was proposed th a t the second cysteine prevents PD I from becoming
trapped, in which PDI could ‘escape’, and reduction follwed by reoxidation of the
substrate disulfides take place in a more timely manner. In more recent studies, PDI
has been found to be involved in other activities such as integrin-dependent adhesion
(Lahav et al., 2000), and denitrosation of S-nitrosothiols (Zai et al., 1999).

8
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M isfolded
S u b s tra te

Native
S u b s tra te

/

R ed u ced
S u b stra te

Figure 1.3: Disulfide rearrangem ent by PDI. A mechanism of disulfide rearrangement
for PDI represents the different pathways th a t may occur during PDI- assisted protein
folding (Schwaller et al., 2003).

9

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

1.1.4

R ed ox C ontrol o f P D I A ctiv ity

PD I is an oxidative enzyme performing its reactions in the less reducing ER
(Raina and Missiakas, 1997), compared to the reducing environment of the cytoplasm.
Thiol content determ ination in PDI is assessed by titratio n w ith 5,5’-dithio-fc-3nitrobenzoate (DTNB). Freshly reduced bovine PD I was revealed to contain 1 free
sulfhydryl and 3 disulfide bonds (Gilbert, 1989), although the exact location of these
groups are not specified. The environment inside the endoplasmic reticulum has been
found to favour therm odynamically the formation of disulfide bonds by increasing
protein stability in the organelle. The conditions of this environment are created by
the relative concentrations of glutathione in its reduced and oxidized form, GSH and
GSSG. In the cytoplasm of cells the [GSH] to [GSSG] ratio is (30-100): 1, whereas
in the ER of cells, it is only 3:1 (Raina and Missiakas, 1997). This difference is
im portant for PD I to stay in the predominantly reduced form, as its prim ary function
is oxidation of proteins in disulfide bond formation. The active site of PD I contains a
redox potential between -110 and -170 mV (Lundstrom and Holmgren, 1993). Outside
of the ER, PD I is more likely to act as a reductant (Noiva, 1999).

1.1.5

P ep tid e B inding

PD I is able to act on a wide spectrum of substrates catalyzing thiol exchange
reactions, and is largely dependent on its ability to bind to polypeptides. In this re
spect, PD I has a

less than 100 fiM, indicating a low affinity for peptides (M orjana

and G ilbert, 1991). In 1999, Koivunen and coworkers identified a peptide binding
site in PDI, separate from the active site, between residues 452-461 in the a ’ domain.
Studies involving m utation or deletion of the b, b ’, and c domain show evidence to
support th a t these domains are involved in peptide binding. M utation of the b ’ do
main reduced isomerase activity (Darby and Creighton, 1998), and deletion of the c
domain inhibited substrate binding activity (Dai and Wang, 1997). PD I exhibits in
creased affinity for polypeptides th a t contain a higher content of Cys residues (Klappa
et al, 1998), which correlates with its prim ary role in protein folding.
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1.1.6

C haperone A ctiv ity

The true definition of a molecular chaperone is to “assist polypeptides to selfassemble by inhibiting alternative assembly pathways th a t produce non-functional
structures” (www.Biology-Online.com 31/05/05).

A well known molecular chaper

one, G roEL/ES undergoes repeated cycles of folding and unfolding, until a more
stable form of its substrate is attained (Todd et al, 1996). In the same respect, PDI
is thought to undergo a similar process in the formation and exchange of disulfide
bonds in proteins (Walker and Gilbert, 1997). Generally chaperones work to inhibit
the aggregation of substrate molecules. PDI does this by rapidly forming disulfide
bonds in its substrate, and using its peptide binding sites to help prevent aggregation
(Quan et al., 1995). Ironically, depending on the concentration of PD I with respect
to the substrate, PD I can act as an anti-chaperone in facilitating aggregation (Puig et
al, 1994). For example, low concentrations of PDI (10 fiM) added to a solution of un
folded and reduced lysozyme causes the formation of insoluble aggregates containing
PDI and lysosyme, but when higher concentrations of PD I (100 //M) are added, ag
gregation ceases (Goldberg et al, 1991). PDI makes up 1% of to tal cell protein, whose
sheer concentration may also assist with the folding process by inhibiting aggregation
of unfolded proteins.

1.1.7

C ell Surface P D I (csP D I)

PDI has shown to be very unique with respect to its functions in the cell. PDI
has been found on the plasm a membrane of platelets (Chen et a l, 1995). This change
in location suggests alternative functions of PDI. In lieu of the traditional activities of
this protein in the ER, it has been involved in mediating integrin-dependent adhesion
(Lahav et a l, 2000) and aggregation (Essex and Li, 1998) in blood platelets. Platelet
adhesion is im portant for blood coagulation, and this adhesion pathway is mediated
by adhesion receptor integrins. It is thought th a t there is disulfide exhange or free
sulfhydryl participation on the integrins. Lahav and coworkers (2000) found th a t by
blocking PD I activity, integrin adhesion is inhibited. Recent studies have also shown
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th a t csPDI also plays a role in nitric oxide release from S-nitrosothiols (Root et al.,
2004), which is discussed in section 1.1.9.

1.1.8

P D I K inetics

In 1989, G ilbert first proposed a mechanism for PDI catalyzed disulfide reduc
tion. Since then, many studies examining the folding pathways of ribonuclease A
(Shin et al, 2002), creatine kinase (Zhao et a l, 2005), and alcohol dehydrogenase
(Primm et al, 1996) have attem pted to delineate models of PD I activity. In the 1989
study by Gilbert, a hexapeptide (CYIQNC) and reduced glutathione (GSH) were used
to probe the kinetic mechanism of PDI. In this study, he examined the PDI-dependent
production of GSSG coupled with the oxidation of GSH by PDI, w ith glutathione re
ductase activity in the presence of excess NADPH. It was found th a t there were three
separate phases of reduction of PDI disulfide bonds: slow (k=0.0019 m in-1 ), medium
(k==0.025 m in-1 ), and fast (k=0.21 min-1 ) (figure. 1.4). The proposed mechanism
is dependent on GSH concentration; elevating the GSH concentration results in an
increase of the reduction of PDI. Unfortunately, kinetic obstacles in early experimen
tation did not account for certain variables such as the auto-oxidation of GSH to
GSSG, the non-enzymatic reaction between the two substrates, and the reduction of
PDI by GSH. Taking these factors into account, a hybrid mechanism was proposed
based on GSH concentration. More current models by G ilbert and colleagues propose
an “escape” mechanism, in which disulfide isomerization involves cycles of reduction
and reoxidation (Schwaller et al, 2003) (figure 1.3). This mechanism also suggests
th a t at increased concentrations of GSH, the rate of isomerization is decreased because
of com petition w ith protein substrate oxidation (Schwaller et a l, 2003). Although
there are no proven enzyme models for PDI, because of the diverse array of substrates
PD I can act upon, PD I may provide a number different options, depending on the
substrate involved.
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Figure 1.4: PD I catalyzed disulfide reduction. The initial mechanism was proposed
in 1989 by Gilbert, b u t had not accounted for kinetic obstacles.
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1.1.9

D en itrosation A ctiv ity o f P D I

Nitric oxide (NO) is most commonly known for its role in sm ooth muscle re
laxation (Bernal-Mizrachi et al., 2005), inhibition of platelet aggregation (Lincoln et
al., 1990), and molecular signalling (Linden et al., 2005). S-nitrosothiols (RSNOs)
are im portant transporters and donors of nitric oxides. Furtherm ore, RSNOs act as
sinks for nitric oxide to prolong its half life, which varies inversely depending on its
concentration in the cell. It has been shown th a t NO transfer from RSNOs is medi
ated by csPDI (Zai et al, 1999). More recent work dem onstrates the ability of PDI
to store NO released from RSNOs, and denitrosate S-nitrosated PD I (PDI-SNO) at
physiological pH (Sliskovic et al, 2005). The proposed mechanism for PDI denitro
sation begins w ith the transnitrosation of the a subunit with RSNO, and leads to the
production of an unstable NO' intermediate with an oxidized enzyme (figure. 1.5).
Implications of this research dem onstrate the im portance of PD I in the movement of
NO bound to RSNOs.
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Figure 1.5: Mechanism for PDI denitrosation. M utus and coworkers (2005), proposed
a denitrosation mechanism with the active site of the a domain in PD I undergoing a
transnitrosation reaction. The intermediate formed is shown to be stabilized by the
imidazole group of His 387 (numbers used are in accordance w ith the sequence found
in appendix A). The final products are an oxidized protein, and NO'.
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1.2

A poptosis
In all living organisms, every cell exists for a finite am ount of time, before it dies.

Cell death can be suicidal, but the death of a few cells may aid in m aintaining tissue
homeostasis. Alternatively, cell death can be uncontrollable by internal cell function,
as it is imposed by outside variables such as physical damage, toxic chemicals, extreme
heat or pressure. Each type of cell death has different features and markers by which
they are characterized.

Cell death by suicide is often referred to as programmed

cell death (PCD), or apoptosis, whereas death by injury is referred to as necrosis.
The term apoptosis was first coined in a 1972 paper by Kerr, Wyllie, and Currie
with the pronounciation of a-poe-to-sis. Classical origins of this term orginate from
Hippocrates (460-370 B.C.) in which he first used the word to describe bone erosion
in relation to tissue death (www.celldeath-apoptosis.org 31/05/05).

1.2.1

Features o f N ecrosis Versus A p op tosis

Until the landm ark study in 1972 by Kerr and colleagues, only necrotic cell death
was studied.

Damage to cells induced by traum a or damage causes cell swelling,

membrane breakage, and release of lysosomal enzymes leading to inflammation dam
aging nearby cells (Gores et al, 1990). Conversely, apoptosis is stim ulated by internal
mechanisms within the cell and is a highly orchestrated process. Apoptosis occurs
during development, in the immune system, in the inflamm atory response, and in
aging (Duke et al., 1996). D eath by suicide is characterized by cell shrinking and
detachm ent, chrom atin condensation, cytoplasmic membrane blebbing, the appear
ance of apoptotic bodies, and phagocytosis of the apoptotic bodies by macrophages
(Kerr et al, 1972) (figure. 1.6). Biochemical features include protein cleavage by
caspases, and the expression of surface markers on apoptotic cells (Nagata, 2000).
A prom inent biochemical feature which distinguishes necrosis from apoptosis is the
DNA fragm entation found in apoptosis, which is visualized as a ladder on an agarose
gel. In necrosis, cell death can be almost instantaneous, in which the DNA remains
undamaged, and this is indicated by a smear on an agarose gel.
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Figure 1.6: Necrosis vs. Apoptosis. The pathway to the left dem onstrates cellular
features of the necrotic pathway. The right side of the figure shows morphological
features of apoptosis (Pollack and Leeuwenburgh, 2001).
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1.3

The Biochem ical M echanism of A poptosis
Cell death can be initiated through four different mechanisms: receptor-mediated

apoptosis, growth factor deprivation, oxidative stress, and g e n o to x ic exp osu re. O nce
the pathway has begun, it can be divided into four different stages of progression
(Hengartner, 2000). Apoptosis begins with a receptor or non-receptor mediated death
signal, which signals the nucleus to initiate a suicide reponse. This is followed by a
control and integration stage in which there is signal transduction, transcription factor
activation, and ATP depletion. In the execution stage, cell death be carried out in
two different pathways; a death receptor pathway (Ashkenazi and Dixit, 1998), or a
mitochondrial pathway (Tatton and Olanow, 1999). Once these pathways have been
initiated, the DNA degradation stage begins, and the cell begins to shrink and bleb,
expressing phagocyte recognition molecules. In the final stage, phagocytosis occurs,
removing dead cells and their debris (figure 1.6).

1.3.1

T he D ea th R eceptor Pathw ay

In the death receptor pathway, the binding of a ligand to a cell surface death
receptor mediates a downstream death signal (Hengartner, 2000). These receptors
belong to the tum or necrosis factor receptor (TNF) family. CD95 (also known as
Fas or A pol), a member of the TN F superfamily (SCOP 49599, CATH 2.60.210.10)
(Murzin et al., 1995, Pearl et al, 2005), contains a characteristic cysteine-rich extra
cellular domain (Smith et al., 1994), and a cytoplasmic “death domain” (Tartaglia
et al., 1993).

Binding of a CD95 ligand (CD95L) to the CD95 receptor leads to

the association of the death domains, and the binding of an adapter protein termed
FADD (Fas-associated death domain) (figure 1.7). FADD contains a “death effec
tor domain” which binds inactive caspase-8 (also known as FLICE or MACH). Once
bound, the oligomerization of caspase-8 initiates self-cleavage, and activation of other
caspases (Ashkenazi and Dixit, 1998). These caspases belong to a family of cysteine
specific proteases (Thornberry and Yuri, 1998), which cleave peptide bonds at the
carboxyl term inal side of aspartic acid residues (Villa et al., 1997). There are many

18

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

other receptors and pathways th a t have been shown to be involved in either initiating
or protecting against apoptosis. The example of the CD95 mediated pathway has
been shown to play a pivotal role in a different type of apoptosis (Nagata, 1997).
These types include inflammatory cell death at “immune-privileged sites” , virus or
cancer-infected cell death by cytotoxic T and natural killer cells, and the deletion of
activated m ature T cells at the end of an immune response (Nagata, 1997).
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1.3.2

T h e M itochondrial Pathw ay

M itochondria have been shown to play a very critical role in the apoptotic
process. The disruption of the mitochondrial membrane potential (A ip) across the
inner membrane causes the leakage of cytochrome c, apoptosis initiating factor (AIF),
and caspase-9 into th e cytoplasm (Kroemer et al., 1997). These three factors together
form an apoptosome, which leads to the activation of downstream caspases involved
in the execution stage of apoptosis (figure 1.8). Although it is still not clear as to how
they are released from the mitochondria, it is believed th a t following a decrease in
mitochondrial membrane potential, a permeability transition pore (P T P ) is opened
in which cyt-c and other mitochondrial proteins are released (T atton and Olanow,
1999). M itochondria are the central location for oxidative phosphorylation, and the
largest producer of reactive oxygen species (ROS) in the cell. Once disrupted, ROS
are generated, and are highly reactive and cytotoxic to the cells (Betteridge, 2000).
ROS has been have been shown to target mitochondrial DNA (Shoji et al, 1995),
m ediate apoptosis (K am ata and H irata, 1999), and even increase the prevalence of
cancer in those individuals exposed to oxidative stress (M arnett, 2000).
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Figure 1.8: A hypothetical model of apoptotic initiation through the mitochondrial
pathway. Following a decrease in mitochondrial membrane potential, a permeability
transition pore (dark ovals) opens and cyt-c and AIF are released into the cytoplasm.
By their associating with caspase-9, an apoptosome is formed, and downstream cas
pases are activated (Modified from Nomura, 2004).
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1.3.3

P D I as a N eu rop rotective P rotein

In a 2000 study, Tanaka and coworkers identified a stress protein up-regulated
in response to hypoxia in glial cells. This protein was identified as PDI, and they
found th a t its overexpression in prim ary cultured glial cells significantly reduced the
loss of cell viability, when subjected to hypoxia. In the same study, Tanaka overex
pressed PD I in different regions of rat brain and subjected them to ischemia. They
observed th a t overexpression of PDI could suppress ischemia-induced apoptosis in
the transfected area. PD I has been examined in conjunction with Alzheimer’s dis
ease (AD), which is characterized by the presence of neurofibrillary tangles, plaques,
and degeneration of nerve cells (Corder et al., 1993). During the development of
Alzheimer’s disease, it was noticed th a t during the shift in the redox balance of cells,
there was no increase in PDI (Kim et al, 2000). These scientists have postulated
th a t the high levels of PD I th a t are found in neurons help to m aintain the redox bal
ance, b u t further oxidative damage may take place, because the concentration of the
protein remains the same. Interestingly enough, PD I was found to be overexpressed
in the brains of individuals with Creutzfeldt-Jakob disease (CJD) (Yoo et al, 2002).
More im portantly, they were able to distinguish th a t PD I did not assist with the
conformational change of the prion protein to a diseased form. Since the finding by
Tanaka and coworkers in 2000, another protein th a t associates with PD I during cell
death has been identified. Ubiquilin, which contains a ubiquitin-like domain and a
ubiquitin-associated domain, are up-regulated during hypoxia in a similar time frame
as PDI (Ko et a l, 2002). Furthermore, ubiquilin is up-regulated in neurons of AD
patients in association with the neurofibrillary tangles (Mah et a l, 2000).
Apoptosis is a physiological requirement for the development and maintainence
of tissue homeostasis. Disruption of this process, in which pathways become uncon
trollable can result in diseases, in which there can be massive cell death, or no cell
death at all. These include diseases such as Alzheimer’s disease, Parkinson’s dis
ease, strokes, AIDS, auto-immune diseases, and cancers. In another example, PDI
was characterized as a negative regulator of NF-reB, which is a transcription factor
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th a t induces an inflamm atory response with acute and chronic immune and regener
ation disorders (Higuchi et al., 2004). It is im portant to continue to study PDI and
understand completely the many ways in which this multifaceted protein functions.
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Chapter 2
D evelopm ent, Expression, and
Localization of P D I and its A ctive
Site D om ain
2.1

O bjectives
Although PD I makes up approximately 1% of total protein content in cells

(Goldberger et al., 1964), an accessible source of human PDI is generally desirable
for experimental studies and assays. Research to study the S-denitrosation activity
of PD I (Sliskovic et al., 2004), S-nitrosoglutathione consumption mediated by PDI
(Root, et al., 2004), and the development of more sensitive assays for the protein,
required a readily attainable source of human PDI. To make this available, human
PDI cDNA was cloned into the bacterial vector pET-28b containing two histidine tags
(at the N-terminus and C-terminus) - see Appendix B. The vector was transformed
into BL21(DE3) E. coli cells for simple purification of the recom binant protein through
Ni2+ affinity chromatography. Also to isolate the source of activity in the protein for
future study, the active site a domain was separately cloned into the pET-28b vector
for further investigation on its copper binding abilities.
C haracteristic of many ER resident proteins, PD I also contains the KDEL signal
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retention sequence. Although found predominantly in the ER, different isozymes of
PDI have been identified in various cell types, which are not localized to the ER. To
visualize the localization of PD I within neuroblastom a cells, hum an PD I cDNA was
fused to green fluorescent protein in the pE G F P -N l vector (Clontech), and transfected
into SH-SY5Y cells. Differentiation of these cells further resolved its locale within
this cell type. PDI, being a redox protein is readily influenced by its environment.
Because PD I is well established as an ER protein, its localization outside of the ER
is examined.

2.2

M aterials and M ethods

2.2.1

C hem icals, B iochem icals, and Supplies

• Bis-Acrylamide solutions were purchased from Bio-Rad Laboratories (Missis
sauga, ON).
• Restriction endonuclease EcoR l, Taq polymerase, direct load wide range DNA
marker, direct load wide molecular weight range protein markers, low molecular
weight range protein marker, ultra-low molecular weight range protein markers,
high capacity nickel chelate affinity m atrix (Ni-CAM HC RESIN), ampicillin,
kanamycin, ribonuclease A (RNase), deoxyribonuclease I (DNase I), lysozyme,
isopropyl/3-D-thiogalactoside (IPTG ), agarose, ammonium persulfate, brilliant
blue R, calcium chloride, ethylenediaminetetraacetic acid (EDTA), glycine, im
idazole, magnesium chloride hexahydrate, potassium acetate, potassium phos
phate, sodium azide, phenylmethyl sulfonyl fluoride (PM SF), sodium chloride,
trizm a base, urea, tryptone, thiamine, tricine, zinc chloride, guanidine hy
drochloride, protease inhibitor cocktail and 3’,3’,5’,5’-tetram ethylbenzidine were
purchased from Sigma Aldrich (Oakville, ON).
• Restriction endonucleases H indlll, PstI, Kpnl, Xhol, and T4 DNA Ligase were
purchased from Prom ega Corporation (Madison, WI).
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• Taq Polymerase was kindly donated by Dr. S. Ananvoranich.
• Oligonucleotides were ordered from Sigma Genosys (Oakville, ON).
• 1 ml tubes were stored in CryoBoxes which were then stored in CryoBox vertical
racks from Nalgene (Rochester, NY).
» Phenol:Chloroform:Isoamyl Alcohol (25:24:1) was purchased from Invitrogen
Life Technologies (Burlington, ON).
• P2, P10, P20, P200, P1000, P5000 Pipetm en from Gilson were supplied by
Mandel Scientific Company Inc. (Villiers-le-Bel, France).
• Plasm id Midi Kit, QIAquick P C R Purification K it and QIAquick Gel Extraction
K it were purchased from Qiagen (Mississauga, ON).
« Yeast extract and granulated agar were purchased from Becton Dickinson and
Company (MD).
• Ammonium chloride, disodium hydrogen orthophosphate heptahydrate, glyc
erol, magnesium sulphate, potassium chloride, sodium dihydrogen orthophos
phate, sucrose, sodium hydroxide and D-glucose were purchased from BDH Inc.
• Amicon U ltrafiltration devices, 10K MWCO (15 ml) were purchased from Millipore (Bedford, MA).
• FuGene 6 transfection reagent was purchased from Roche Diagnostics (Laval,
QB).
• Hoechst Dye 33342, M itotracker Red 580, Annexin V 594 (Molecular Probes,
USA), and Brain Derived Neurotropic Factor (Alomone Labs, Israel) were kindly
obtained from Dr. S. Pandey.
• Geneticin G418 was purchased from Gibco (Burlington, ON).
• Polyclonal rabbit anti-PD I antibody was purchased from Abeam (Cambridge,
MA).
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• A nti-goat horseradish peroxidase antibody was kindly obtained from Dr. B.
M utus.

2.2.2

B acterial Strains and Plasm ids

• pE T 28b (Novagen).
• pE T 11a (Novagen) containing PDI cDNA was kindly obtained from Dr. B.
M utus. It was a gift from X. Jiang.
• p E G F P -N l (Clontech).
• BL21(DE3) E.coli cells (Invitrogen Life Technologies).

2.2.3

A pparatus and Instrum entation

• Acrylamide gels were cast on a Hoefer Mighty Small SE 245 Dual Gel Caster,
and acrylamide gel electrophoresis was conducted using a Hoefer Mighty Small
II SE 250 Mini-Vertical Gel Electrophoresis Unit, both from Amersham P har
m acia Biotech (Laval, QB).
• Agarose was melted in a 0.6 cubic foot microwave oven from Magnasonic (ON,
C anada).
• Gel casting and agarose gel electrophoresis were conducted in a Horizon 58
Horizontal Gel Electrophoresis A pparatus from Gibco BRL Life Technologies
(Burlington, ON).
• Samples were weighed on a M ettler AE50 scale from Cambridge Scientific (MA,
USA).
• Larger samples were weighed on a Ohaus Compact scale from Ohaus Corpora
tion (NJ, USA).
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• Agarose gels stained with ethidium bromide were viewed and photographed on
the Alphalm ager 2200 Light Imaging System with AlphaEase software from
A lpha Innotech Corporation (San Leadro, CA).
• Agarose gels stained with ethidium bromide were viewed using the Benchtop
Ultraviolet Transillum inator from VW R Scientific (ON, Canada).
• The Agilent 8453 UV-visible spectrophotom eter from Agilent Technologies (ON,
Canada) was used to measure protein concentration, enzyme activity, and cell
culture growth and density.
• Polymerase Chain Reactions (PCR) were carried out in a 48-well Perkin Elmer
Cetus DNA therm al cycler from Perkin Elmer, (CT, USA).
• Centrifugations were performed using an Fisher Model 59A microcentrifuge
from Fisher Scientific (ON, Canada).
• pH measurement of buffers and solutions were done using pH M eter Model 420A
by ORION (ON, Canada).
• Insulin turbidity assay was measured on the U ltra M icroplate ELx808/[/ from
BIO -TEK Instrum ents, Inc. (VT, USA).
• Incubations at 37°C with agitation were done in the C25 Incubator Shaker
Classic Series by New Brunswick Scientific Co., Inc.
• Cell lysis was performed using the Sonic Dismembrator Model 100 from Fisher
Scientific (ON, Canada).
• B acteria grown on agar plates were incubated in the Model 1510E Incubator by
VW R Scientific (ON, Canada).
• H eating and boiling of protein samples were in the Canlab block heater by
American Hospital Supply C anada Inc.
• All microscopy was performed on the Leica DM IRB Microscope from Leica
Microsystems (Germany).
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• All pictures were taken using a Qlmaging camera.
• DCFDA fluorescence was measured with the Spectra Max Gemini XS multi-well
plate fluorescence reader (CA, USA).
• Centrifugation was performed on a J2-HS Beckman centrifuge with JA-10, JA14, and JA-20 rotors.
• Ischemic conditions were simulated with the Gas Pack System from Becton
Dickenson (Cockeysville, MD).
• Dessication of protein was done in the Labconco Model 4451F Lyophilizer,
Labquip Limited (Markham, ON).
• DNA sequencing was performed at Wayne State University DNA Sequencing
facility.

2.2.4

C ell Lines and M edia

Human umbilical vein endothelial cells (HUVEC) were purchased from the
American Type Culture Collection (ATCC), and were m aintained in K aighn’s F12K
medium (Gibco, Canada) containing 1.5 g/L sodium bicarbonate, 2 mM L-glutamine,
and supplem ented with 0.1 m g/m l heparin (Sigma, Canada), 10% fetal bovine serum
(Gibco, C anada), and 0.03-0.05 m g/m l endothelial cell growth supplem ent (BD Bio
sciences, USA). Human Neuroblastoma (SH-SY5Y) cells were also purchased from
ATCC, and m aintained in Dulbecco’s Modified Eagle M edium H am ’s F12 media
(Sigma, Canada) containing 1.5 g/L sodium bicarbonate, and supplemented with
10%i fetal bovine serum (Gibco, Canada), and 2 mM L-glutamine (Gibco, Canada).

2.2.5

G eneral D econtam ination and Sterilization Procedures

All glassware, pipette tips, centrifuge tubes, and Milli-Q w ater used for both
bacterial and mammalian cell culture were autoclaved to avoid bacterial and fungal
contamination. All supplies used in the cell culture laminar flow hood were sprayed
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with 70% ethanol. The laminar flow hood was sterilized each day with an ultraviolet
lamp.

2.3

P rotein and Bacterial Work

2.3.1

P D I cD N A E xpression C loning in B acterial Cells

The plasmid vector p E T -lla containing PDI cDNA, was verified by sequencing
prior to use for cloning. An expression construct was derived using Taq polymerase
and primers (forward 5-AAAGAATTCAGACGCCCCCGAGGAGGAGGAC-3; re
verse 5-CCCA GG CTTCAG TTCATCTTTCACA G CTTTCTG ATC-3) which brack
eted the open reading frame of PDI cDNA and possessed restriction sites for Eco R I
and Hind III, respectively, to facilitate insertion into pET-28b. Prim ers were gen
erated by Sigma Genosys and designed by the custom created com puter program
w ritten by R. Nistor and D. Seslija found in Appendix C. Polymerase chain reaction
was carried out in a to tal volume of 100 fA, containing 20 mM ammonium sulfate, 75
mM Tris-HCl (pH 8.8), 5 mM MgCl2 , 20 fiM of each dNTP, 50 pmol of each primer,
500 ng of p E T - lla tem plate, and 2 units of Taq DNA polymerase. PC R was run for
30 cycles (95°C for 60 seconds, 55°C for 30 seconds, 72°C for 80 seconds. Samples
were stored at 4°C until further use (Gibbs, 1990). T he insert and vector were ligated
together using T4 DNA ligase, according to directions by Promega. The construct
was transform ed into E. coli strain BL21(DE3) using the calcium chloride protocol
(Sambrook et al., 1989) and grown on agar plates containing 10 m g/L of kanamycin.
The presence of PD I cDNA insert in bacterial cells was then verified by screening
colonies from the plates, followed by plasmid extraction (Novagen pE T manual pro
tocol) and digestion w ith the restriction enzymes EcoR I and H indlll. The restriction
digest was analyzed on a 1.5% agarose gel (Sambrook et al., 1989). Wayne State
University DNA Sequencing facility verified the presence of the fusion product.
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2.3.2

P D Ia cD N A E xpression C loning in B acterial Cells

An expression construct was derived using Taq polymerase and primers (forward
5-AAAGAATTCAGACGCCCCCGAGGAGGAGGACCACGTCCTG-3; reverse 5-TT
TAAGCTTG GCA G CCGG G CCCG TGCGCTTCTTCA G CCA -3) which bracketed the
open reading frame of the active site a domain (PDI-a), and possessed restriction sites
for E coR I and H in d lll, respectively, to facilitate insertion into pET-28b (refer to Ap
pendix B). Prim er construct and P C R were done as described in section 2.3.1. The
insert and vector were ligated and transformed into E. coli BL21(DE3). Cells were
m aintained on agar plates containing 10 mg/1 kanamycin plates. The presence of the
a-domain was verified by sequencing at the Wayne State University DNA sequencing
facility.

2.3.3

P urification o f th e R ecom binant P rotein s

B acterial cultures containing the recombinant plasmid were induced with 1 mM
IPTG overnight at room tem perature. Cultures were centrifuged at

6

000 rpm in a

JA-10 rotor for 20 minutes at 4°C and the supernatant was discarded. The pellet
was resuspended in cell lysis buffer (3 m l/g of pellet). Lysozyme was added to the
suspension to a final concentration of 0.3 m g/m l and shaken at 4°C for 30 min.
Sodium deoxycholate (1 m g/m l), DNase I (6.7 m g/L), and RNase (6.7 m g/L) were
added to the lysate and shaken at 37°C for 20 minutes, until the m ixture was no
longer viscous. The cell suspension was sonicated 3 times for 30 seconds at level 7.5
on the Sonic Dismem brator, and the mixture was then centrifuged at 15 000 rpm on a
JA-20 rotor for 20 min at 4°C. The pellet was kept on ice, while the supernatant was
added to the nickel column. The recombinant fusion protein was isolated using nickel
affinity chromatography. All steps were performed at 4°C unless otherwise stated.
Prior to loading the crude extract, 1.5 ml of nickel resin suspension was prepared
according to the Sigma product manual protocol. The crude extract was then shaken
gently at 4°C for 30 minutes. The crude extract-resin m ixture was then packed into a
20 ml polypropylene column and loaded at a flow rate of 1 m l/m in. The flow through
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was collected and reserved for SDS-PAGE. The resin was then washed with 30 ml
of 10 mM imidazole wash buffer or until the optical density (OD) measured at 595
nm was com parable to the blank. The resin was then washed w ith 30 ml of 30 mM
imidazole, or until the OD 595 was similar to the blank. Further non-specifically bound
proteins were washed with 10 ml of 100 mM imidazole, and finally, the target protein
was eluted w ithin the first 4 ml of 250 mM imidazole elution. The eluted protein was
collected in 1 ml fractions, and its concentration was determ ined using the Bradford
reagent. To confirm the presence of the isolated his-tagged protein, PDI, and PDI-a
were analysed together on a 13.5% SDS-PAGE and then stained w ith Coomassie blue.

2.3.4

Im m unoblot A nalysis

Purified recombinant protein was run on a 13.5% SDS-PAGE gel, and electrophoretically transferred to nitrocellulose membrane using transfer buffer (2 0 %
methanol, 24 mM tris base, 0.2 M glycine)(Sambrook et al, 1989). After transfer,
the blot was tem porarily stained with a 1:9 dilution of Ponceau S for 10 minutes,
and washed w ith water. The blot was placed in Tris Buffered Saline (TBS - 0.02 M
Tris HCL, 0.2 M NaCl, pH 8.2) solution with 5% skim milk for 2 hours at room
tem perature, to block non-specific binding sites on the membrane. Incubation with
prim ary polyclonal rabbit anti-PD I antibodies at a 1:1000 dilution in TBS with 2%
skim milk was done overnight at 4°C. The membrane was then washed with TBS
twice for 10 minutes. For detection of polyclonal anti-PD I antibody, the membrane
was incubated with the secondary antibody horseradish peroxidase anti-goat IgG at
a 1:2000 dilution in TBS with 2% skim milk at 4°C for 2 hours. The membrane was
then washed for 30 minutes with TBS. Visualization was performed by adding 5 ml
of 3’,3’,5’,5’-Tetram ethylbenzidine producing a perm anent blue reaction product.

2.3.5

Insulin Turbidity A ssay

To test the activity of both recombinant proteins, the experiment described by
Holmgren (1979) was modified for a 96-well plate. 4 mM D TT, 2 /j M enzyme sample,
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and 1 mM insulin were added to the assay buffer (0.1 M K 2 H PO 4 , 2 mM EDTA, pH
7.0) to a volume of 200 fil. Absorbance was monitered using the kinetics mode at 650
nm at 0.5 m inute intervals for 30-45 minutes.

2.3.6

P D I cD N A E xpression C loning in B acterial C ells for
M am m alian Expression

An expression vector for protein localization was derived using Taq polymerase
and forward primers 5-AAAAGAATTCTTATGGACGCCCCCGAGGAGGACGAC3; reverse prim er 5-AAATGGTACCTGCAGTTCATCTTTCACAGCTTTCTGATC3) which bracketed th e open reading frame of the PD I cDNA, and possessed restric
tion sites for Eco R I and Kpn I, respectively, to facilitate insertion into pE G F P -N l
(refer to A ppendix B). The insert and vector were ligated and transform ed into E.
coli BL21(DE3) as described previously in section 2.3.1. Cells were maintained on
agar plates containing 10 m g/L kanamycin. The construct was also verified through
sequencing by Wayne State University DNA Sequencing facility.

2.3.7

H U V E C Transient Transfection

A standard protocol for calcium phosphate-m ediated transfection (Sambrook et
al., 1989) was performed on the HUVECs. Plasmids p E G F P -N l and PD I:pE G FP-N l
were prepared using the Qiagen midiprep kit, and DNA concentration and purity were
measured at an absorbance of 260 nm and 280 nm (Glasel, 1995). Visualization of
the plasmid DNA was executed on a 1.5% agarose gel. HUVEC transfection was also
attem pted using FuGENE

6

transfection reagent, according to the m anufacturer’s

protocol (Roche Diagnostics).
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2.3.8

In Vitro Transfection by a L iposom al reagent in SHSY 5Y Cells

FuGENE

6

transfection reagent was used to transfect SH-SY5Y cells, according

to the m anufacturer’s protocol (Roche Diagnostics). p E G F P -N l and PD I:pE G FP-N l
plasmids were prepared using the Qiagen midiprep kit, and DNA concentration and
purity was measured as described in section 2.3.7. Success of transfection was verified
by observation of the green fluorescence of cells under a UV lamp with a G FP filter.

2.3.9

D eterm in ation of G418 S en sitivity on S H -S Y 5Y Cells

A set of eight (35 m m 2 x 10mm2) plates were prepared by splitting a confluent
25 m m 2 flask so the cells were 25% confluent in 24 hours. The next day the culture
medium was replaced with medium containing varying concentrations of G418 (0,
50, 150,

200

, 300, 400, 500, 800 Aig/ml G418). G418 was used to select against cells

th a t did not contain the pE G F P -N l plasmid. The selective m edia was changed every
48 hours, and the percentage of surviving cells was observed. The concentration of
antibiotic G418 th a t prevented cell growth within two weeks was chosen (Tzen et al,
1990).

2.3.10

G eneration of a Stable Cell Line in S H -S Y 5Y Cells

Two sets of SH-SY5Y cells were transfected with either pE G F P -N l plasmid,
or PD I:pE G FP -N l plasmid. Forty-eight hours post transfection, the cells were split
into a 1:3 ratio, w ith medium containing the 200 /jg/m l of G418. The cells were fed
with selective medium every 48 hours for one week, until colonies of stable cells were
identified w ith fluorescent microscopy. Cells were then transferred into 24-well plates
for growth and expansion.
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2.3.11

Effect o f C oenzym e Q i0 (C oQ i0) on Im proving the
L ifetim e o f Stable Cells

Following the generation of stable cell lines, cells were lifted from the 24-well
plate, and transferred to 35 mm 2 x

1 0 mm 2

plates.

1

/d of CoQio (50 m g/m l) was

added for each millilitre of media, for half of the plates. Cells were examined for
vitality and the absence of senescent cells, in comparison to those plates without
CoQio-

2.3.12

P reparation o f th e Total Cell Lysate

Following experimental assays, the cells were washed twice w ith 1 X PBS, pH
7.4, and then incubated at 4°C with TN TE buffer (0.5% Triton X, 150 mM NaCl, 50
mM Tris, pH 7.5, 1 mM EDTA) for 15 minutes. Cells were harvested by mechanical
dislodging w ith a rubber policeman, and the lysate was spun at 5 000 rpm in a JA-20
rotor for 5 minutes. The supernatant was removed, and the pellet was resuspended
in 200 pi of T N T E buffer containing 10 pi of protease inhibitor cocktail (prepared
as described in the Sigma product information). The concentration of the total cell
lysate was estim ated using the Bradford reagent at an absorbance of 595 nm.

2.3.13

Im m unoprecipitation

Cells were lysed as described previously (section 2.3.12), and the concentration
of protein used was 1 m g/m l. Polyclonal rabbit anti-PD I antibodies were added to
the to tal cell lysate to a dilution of 1:100. The m ixture was incubated on ice for
two hours. Approximately 50 pi of Protein A agarose beads were added for every
200 /A of cell lysate, and the solutions were rocked at 4°C for two hours. The beads
were collected by microcentrifugation at maximum speed and washed three times
with 1 ml of T N T buffer (same as TN TE minus the EDTA). The supernantant was
removed, and the beads were resuspended in 50 pi of 2X loading buffer, and boiled for
5 m inutes at 100°C. Products were loaded onto a 10% SDS-PAGE gel, and subjected
to a W estern blot.
36
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2.3.14

S H -S Y 5Y D ifferentiation

Differentiation of SH-SY5Y cells were carried out using a previously described
m ethod (Encinas et al., 2000). Cells were plated in 35 mm 2 petri plates, pre-coated
with 0.05% collagen. Twenty-four hours later, all-trans retinoic acid was added to a
final concentration of 10 /dVf, in F12 medium containing 15% Fetal Bovine Serum for
5 days. Following, the cells were washed twice with F12 medium and incubated with
50 ng/m l Brain Derived Neurotropic Factor (BDNF) in serum free media for seven
days.
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2.4

R esults

2.4.1

D evelop m en t and E xpression o f P D I in B acteria

To clone the sequence of full length PDI (approxim ately 1490 nucleotides) into
pET-28b, amplification of the human PDI cDNA sequence was performed from the
p E T -lla vector containing PDI cDNA, using P C R with primers flanking the cDNA
sequence of PD I (figure 2.1). Bands of approxim ately 1.5 Kilobases (Kb) were iden
tified to be amplified PD I cDNA. Two bands of 0.38 Kb and 0.05 Kb were found and
indicate non-specific primer binding, due to the identical sequences of the a and a ’
domain. Annealing tem peratures of 55°C (lane 2) and 60°C (lane 3) were used in the
PC R reactions. There was no m ajor difference in P C R product with the five degree
tem perature differential. P C R cDNA from lane 3, at a molecular weight of 1.5 Kb,
was used for ligation to the pET-28b vector.
Following ligation of the insert to the vector, colony screening and restriction
enzyme digestion was done with EcoR I and H indlll. The band observed at 1.5 Kb
indicated the presence of PD I cDNA in the pET-28b vector (lane 4 - figure 2.2). The
5.4 Kb band in lane 4 of figure 2.2 was the pET-28b plasmid. Lane 2 indicates the
molecular weight of pET-28b plasmid, which is 5.4 Kb. Bands located higher than
the molecular weight ladder indicate a linear conformation of th e plasmid, as opposed
to its coiled or supercoiled forms which migrate more easily through the gel. Lane
3 indicates the the observed molecular weight of the ligated pET-28b:PDI plasmid
which is 6.9 Kb. The digested pET-28b:PDI plasmid in lane 4 clearly indicates the
molecular weight of the cDNA as 1.5 Kb.
The sequence of the reading frame from the 1.5 Kb piece of DNA of the recom
binant plasmid was aligned with the cDNA sequence originally obtained from the
pET-1 la:P D I plasm id,and GenBank accession number E03087 (human PDI) giving
99.8% sequence identity. Base pair differences were due to the lack of identification
of some base pairs, due to signal weakness, and lack of base pair identification in
the chrom atograph obtained from the Wayne S tate sequencing facility. The DNA
sequence was consistent with the correct protein sequence.
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Similarity, cDNA amplification specific to the a domain (approxim ately 380 nu
cleotides) of PD I yielded bands of 0.38 Kb (figure 2.3). Again, non-specific primer
binding was present in both lanes, as indicated by the additional bands found at 0.05
Kb. Colony screening and restriction enzyme digestion showed the presence of the
0.38 Kb insert in the pET-28b vector (lane 2 - figure 2.4). Sequence identity between
the a domain and full length PDI yielded 99.3% identity. Base pair differences were
due to the lack of identification of some base pairs, due to signal weakness in the
chrom atograph obtained from the Wayne State sequencing facility.
Expression of each recombinant protein yielded approxim ately 1 8 - 2 5 mg of pro
tein per 1 litre of bacterial culture. The presence of full-length PD I and PD Ia protein
were visualized by bands of approximately
figure 2.5, lane

6

66

KDa, and 19 K Da respectively (lane 7 -

- figure 2.6). The increase in molecular weight by approximately 9.5

KDa of both recom binant proteins was due to the presence of both an N-terminal and
C-terminal His 6 tags. Removal of the N-terminal His-tag would theoretically result
in molecular weights of 61 KDa for full length PDI, and 14 K Da for the active site
domain.
A W estern blot further confirmed the presence of PDI and PD Ia (lanes 1 and 2 figures 2.7 and 2.8). Repeated detection of a weak band at twice the molecular weight
(132 KDa) of full-length PD I agrees with the assumption of native PD I existing as a
homodimer (Noiva, 1999). The insulin turbidity assay (figure 2.9) indicates th a t the
activity of the full-length recombinant PDI is comparable to th a t of Sigma bovine
PDI; the activity of the a domain showed comparable results, based on its capacity as
a single domain. Removal of the N-terminal His 6 tag through cleavage with thrombin,
but its removal was found to have no effect on the activity of the protein (data not
shown).
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2.4.2

D evelop m en t, Expression, and L ocalization of P D I in
S H -S Y 5Y Cells

To develop a live cell reporter protein sy ste m c o n stitu tiv c ly expressing PDI, Nterm inal fusion of full-length human PDI to G FP was done using vector pE G F P -N l
(Clontech). Using primers flanking full-length PDI, P C R was used to amplify its
sequence from the p E T -lla vector (lane 2 - figure 2.10). A band of approxim ately 1.5
Kb was identified to be PD I cDNA. Bands found at 0.38 Kb and 0.05 Kb were again
considered to result from non-specific primer binding. Following ligation of the 1.5
Kb insert to the p E G F P -N l vector, colony screening followed by restriction enzyme
digest w ith enzymes E coR l and K p n l, indicated the presence of the 1.5 Kb full length
PDI cDNA w ithin the vector (lane 4 - figure 2.11). Sequence alignment of the ex
perim entally determ ined reading frame from this recombinant plasmid was compared
with the cDNA sequence obtained from the p E T -lla :P D I plasmid, giving a 97.6%
sequence identity. Base pair differences were due to the lack of identification of some
base pairs, due to signal weakness in the chrom atograph obtained from the Wayne
State sequencing facility. There was no noticeable effect on the protein sequence.
HUVEC cells were chosen initially chosen as the target of mam m alian cell trans
fection, based on their role in nitric oxide transport. However, attem pts using both
calcium phosphate, and liposomal (FuGene) mediated transfection were unsuccessful,
based on th e transfection efficiency of this particular cell type. Instead, transient
and stable cell lines of SH-SY5Y neuroblastoma cells were generated using FuGene

6

transfection reagent. Cells were maintained at a concentration of 200 p g /m l of G418,
and it was found th a t the addition of 0.05 m g/m l of CoQio had no noticeable effects on
reducing the number of senescent cells after 10 population doublings. Presence of the
reporter protein in SH-SY5Y cells was verified by im m unoprecipitation (figure 2.12).
The molecular weight of G FP alone is approximately 27 KDa, and the molecular
weight of PD I alone is approximately 57 KDa, together, w ith the presence of a small
linker region between the two proteins, yields a molecular weight of approximately
87 KDa. The 87 KDa band visible in lane one of figure 2.12 shows the presence of
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the P D L G FP reporter protein in the transfected cells. T he band at approximately
57 kDa identifies the endogenous level of PD I found in the cells. Protein localization
of PD I was examined in a stable cell line of differentiated SH-SY5Y cells. Cells were
observed for areas of green fluorescence, which was found throughout the cell, includ
ing the cytoplasm and dendrites (figure 2.13). Green fluorescence was also observed
within the nucleus, and arrows indicate the absence of PD L G FP in the nucleoli of
the cells.
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2.5

D iscussion
The study of protein structure and function has been greatly aided by the de

velopment of systems th a t are able to regulate protein expression. More specifically,
recombinant protein systems allow for the controlled expression of copious amounts
of proteins, otherwise too difficult to obtain from their natural in vivo conditions.
Full-length PD I and its active site domain were produced in E. coli as soluble pro
teins, w ith the addition of 2 Hisg tags located at the N and C-termini of each protein,
to aid in purification. The isolated recombinant full-length PD I exhibited enzymatic
activity similar to commercially available bovine PDI, as verified with the insulin
turbidity assay. Enzym atic activity of the active site domain a showed a functional
protein, b u t only at a 61% level of the full length protein. Kinetic param eters cannot
be deduced from the insulin assay under these conditions, as it was ju st used to test
the relative activity of the protein for functionality purposes. The characterization of
the functional properties of both a and a ’ domains in work by Darby and Creighton
in 1995, compared the activity in the reactivation of disulfide-scrambled ribonuclease
A, disulfide folding of B PTI, and disulfide formation in model peptides. In these
instances, the two active site domains were shown to be efficient in their ability to
introduce disulfide bonds in unfolded proteins, b u t were less efficient th an full length
PDI in disulfide bond isomerization. The engineering of a recom binant full-length
PDI was created to assist the study and characterization of th e S-nitrosation activity
of PDI. It was shown th a t PD I denitrosates S-nitrosoglutathione (GSNO), and th a t
by auto-S-nitrosation of the active site through N 2 O 3 , PDI can act as a NO carrier
(Sliskovic et al., 2005).
In studying PD I kinetics, it has been difficult to estim ate initial rates of enzyme
turnover. It has also been difficult to determine Michaelis-Menten param eters of PDI;
enzyme rates increase as enzyme concentration is increased, and there are long lag
phases before reactions are detectable. Many models of its mechanism have been
proposed, b u t all lack experimental evidence to support them. In a study by Raturi
and coworkers (2005), a more sensitive assay for PD I was developed, based on the
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PDI-dependent reduction of a synthetic fluorescent self-quenching probe di (o-amino
benzoyl) glutathione disulfide (diabz-GSSG). The reduction of diabz-GSSG to (0amino benzoyl)-glutathione (abz-GSH) by PD I results in an increase in fluorescence;
it utilizes low concentrations of PDI, in an immediate reaction th a t can easily be
monitered spectroscopically.
Coenzyme Q10 is the electron transporter in the mitochondrial respiratory chain,
and has been shown to reduce apoptosis (Moon et al., 2005). Addition of coenzyme
Q10 to th e cell media was done as an attem pt to preserve transfected cells, and de
lay senesence of the stably transfected cells. Unfortunately, no noticeable differences
were seen in generating and maintaining stable cell lines between those cells receiving
0.05 m g/m l of coenzyme Q10, and the cells receiving no extra treatm ent in its place.
Although traditionally thought of as an enzyme localized specifically to the ER, more
recent studies have shown th a t PDI is found throughout the cell. Cell surface PDI was
identified on the surface of human blood platelets (Chen et al., 1995), mitochondrial
PDI was found in ra t liver cells (Rigobello et al., 2000), and PD I has been located
throughout the cytosol in astrocytes of glial cells (Safran et al., 1991). In this study,
the localization of PD I in differentiated human neuroblastom a cells shows the disper
sal of PD I throughout the cell, and into the dendridic arms, indicating th a t it is not
only localized to the ER in SH-SY5Y cells. Implications for th e potential purpose of
this protein throughout the cytosol of these cells is discussed in section 3.4.
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Figure 2.1: cDNA amplification of full-length PDI. An image of the 1.5% agarose gel
resolution of the P C R products. Lane 1 contains a DNA marker ranging from 10 Kb
to 0.05 Kb. Lane 2 contains amplified PDI cDNA under an annealing tem perature of
55° C, and lane 3 contains amplified PD I cDNA under an annealing tem perature of
60°C.
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Figure 2.2: pET-28b:PDI fusion and restriction enzyme digest.

An image of the

1.5% agarose gel resolution of the plasmid extraction and restriction enzyme digest
products. Lane 1 contains the DNA marker, lane 2 contains pET-28b plasmid, lane 3
contains recom binant pET-28b:PDI, and lane 4 contains the restriction enzyme digest
of pET-28b:PDI by restriction enzymes E coR l and H indlll.
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Figure 2.3: cDNA amplification of the active site domain of PDI. An image of the
1.5% agarose gel resolution of the P C R products. Lane 1 contains amplified PDI
cDNA under an annealing tem perature of 55° C, lane 2 contains amplified PDI cDNA
under an annealing tem perature of 60°C, and lane 3 contains th e DNA marker.
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Figure 2.4: pET-28b:PD Ia fusion and restriction enzyme digest. An image of the 1.5%
agarose gel resolution of the restriction enzyme digest products. Lane 1 contains the
DNA marker, lane two contains the restriction enzyme digest of pET-28b:PD Ia by
restriction enzymes E coR l and H indllL
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Figure 2.5: Protein purification of recombinant PDI. An image of a 12% acrylamide
gel containing recom binant PDI. Lane 1 contains the molecular weight (MW) markers
ranging from 205 K Da to 6.5 KDa.

Lane 2 contains protein eluted with 10 mM

imidazole; lane 3 contains a second elution with 10 mM imidazole; lane 3 contains a
third 10 mM imidazole wash; lane 4 contains protein eluted with 30 mM imidazole;
lane 5 contains a second 30 mM wash, and lane

6

contains recombinant protein eluted

with 250 mM imidazole.
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Figure 2.6: Protein purification of recombinant PDIa. An image of a 17% acrylamide
gel containing recom binant PDIa. Lane 1 contains a M W marker ranging from

66

KDa to 6.5 KDa. Lane 2 contains insoluble proteins in th e pellet; lane 3 contains
proteins eluted with a 10 mM imidazole wash; lane 4 contains a second 10 mM
imidazole wash; lane 5 contains proteins eluted w ith a 30 mM imidazole wash, and
lane

6

contains recom binant protein eluted with 250 mM imidazole.
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Figure 2.7: Ponceau-S stain of nitrocellulose prior to immunoblotting. Lane ] contains
recombinant PD Ia protein; lane 2 contains recombinant PD I protein; lane 2 contains
Sigma bovine PDI; lane 4 contains Bovine Serum Albumin (BSA), and lane I contains
a MW marker ranging from

66

KDa to 6.5 KDa.
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Figure 2.8: W estern blot of PDI and PDIa. An image of th e colorimetric development
by 3’,3’,5’,5!-Tctram ethylbenzidine after immunoblotting. Lane 1 contains recombi
nant P D Ia protein; lane 2 contains recombinant full length PD I w ith 2 His 6 tags; lane
3 contains Sigma bovine PD I (positive control), and lane 4 contains BSA (negative
control).
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Figure 2.9: Insulin turbidity assay of the recombinant proteins. Sigma bovine PDI
and recom binant hum an PDI show similar enzymatic activity. Recombinant PD Ia is
active, b u t its activity is decreased in comparison to full-length PDI.
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Figure 2.10: cDNA amplification of full-length PDI. An image of the 1.5% agarose
gel resolution of the P C R products. Lane 2 contains amplified PD I cDNA under an
annealing tem perature of 55°C, and lane 1 contains the DNA marker.
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Figure 2.11: p E G F P -N l:P D I fusion and restriction enzyme digest. An image of the
1.5% agarose gel resolution of the plasmid extraction and restriction enzyme digest
products. Lane 1 contains the DNA marker; lane 2 contains plasmid pE G F P -N l; lane
3 contains recom binant plasmid pEG FP-N l:PD I. In lanes 2 and 3 the linear, coiled,
and supercoiled forms of the plasmid are observed. Lane 4 contains the restriction
enzyme digest of plasmid pE G F P -N l:P D I by restriction enzymes E coR l and KpnI.
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Figure 2.12: Im m unoprecipitation of SH-SY5Y cells expressing the reporter protein.
Lane 1 contains im munoprecipitation of the total cell lysate from transiently trans
fected SH-SY5Y cells. Lane 2 contains the control im m unoprecipitation of the total
cell lysate from untransfected SH-SY5Y cells.
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Figure 2.13: Localization of PDI in differentiated SH-SY5Y cells. Photos above (A
and B) and below (C and D) compare cell morphology and reporter protein localiza
tion of selected cells. Photos A and C were taken under phase contrast microscopy,
whereas photos B and D were taken under a fluorescent microscope, containing a blue
UV filter. Arrows shown in B and D indicate the absence of PD L G FP in the nucleoli
of the cells.
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Chapter 3
Further Evidence of P D I as a
N europrotective Protein
3.1

O bjectives
In various stressful situations, PD I has been shown to be upregulated.

For

example, in prim ary cultured glial cells, the protein was upregulated under hy
poxic/ischemic conditions (Tanaka et al, 2000). Overexpression was also demon
strated in the brains of patients with CJD (Yoo et al, 2002). In the previous chapter
the localization of the protein in SH-SY5Y cells was probed by creating a PD LG FP
construct. To investigate further the properties of PDI as a neuroprotective protein,
stable lines of SH-SY5Y cells were generated containing the PD L G F P construct. The
promoter under which gene expression was controlled was the cytomegalovirus im
mediate early (CMV IE) promoter, which is constitutively active. In introducing
excess PD I to SH-SY5Y cells, it was anticipated th a t a similar outcome demon
strated by Tanaka, would occur under stressful conditions, and work to protect the
cells. Furtherm ore, Bruening and coworkers (1998) identified th a t the activation of
stress-activated mitogen activated protein kinases (MAPK) upregulated the expres
sion of transgenes under control of the CMV IE promoter, and during ischemic stress
members of th e M APK family are activated (Moriya et al, 2000). If the CMV IE
promoter is activated through cell stress, then the PD L G FP construct would be over57
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expressed in the stable cell lines. This chapter sets out to examine further evidence
of PD I as a neuroprotective protein under conditions of oxidative and ischemic stress
in SH-SY5Y cells.

3.2

M ethods

3.2.1

Inducing O xidative Stress by H 2 O 2 Treatm ent

Oxidative stress was induced by adding H 2 O 2 to a final concentration of 100 /jM
to the untransfected control cells, and to the pE G F P -N l and P D I:pE G FP -N l trans
fected cells. After one hour, the media was changed, and the plates were incubated
for three hours at 37°C, 5% CO 2 . A poptotic assays followed three hours after the
treatm ent (Naderi et al., 2003).

3.2.2

Inducing H ypoxia

Cell m edia was replaced with a controlled salt solution (110 mM NaCl, 5.4 mM
KC1, 0.8 mM M gCb, 1.8 mM CaCl 2 , 15 mM NaHCOa, 15 mM glucose, 15 mM hepes,
and 50 mM glycine, pH 7.4). Cells were put in a Gas Pack (anaerobic vessel) with
a catalyst th a t consumed the remaining oxygen in the tank. An anaerobic indicator
was used to m oniter the decrease in oxygen. The cells were left in the tank for

6

hours, and m edia was changed (Munir et al., 1995). The cells were monitered by
counting the number of live cells per 100 in three different areas in 35 mm 2 plates
over a 48 hour tim e period. Three trials were done and three sets of measurements
were taken for each. Averages were taken for each trial, and percentage error was
calculated between all trials.

3.2.3

C ellular Staining and M icroscopy

SH-SY5Y nuclei were stained by adding Hoechst 33342 dye (Molecular Probes)
to a 10 fiM final concentration to cell media and incubating for 10 minutes. Mitochon
dria were stained by adding M itotracker dye (Molecular Probes) to a 100 nM final
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concentration to the cell media. Phosphatidylserine in the cell membrane was stained
by adding 1.5 /il of Annexin V 594 (Molecular Probes) per 3 ml of annexin-binding
buffer (10 mM H EPES, 140 mM NaCl, 2.5 mM CaCl 2 , pH 7.4), and incubating for
15 minutes. Following incubation of the Hoechst and M itotracker dyes, the media
was removed and replaced with IX Phosphate Buffered Saline (PBS) pH 7.4. The
cells were examined under a fluorescent and phase contrast microscope. Photos were
taken a t 100, 400, and 600 x magnification and processed using Adobe Photoshop 6.0
software.

3.2.4

R ed uced G lu tath ion e (G SH ) M easurem ents

Control and transfected SH-SY5Y cells were treated w ith 100 /iM H 2 O 2 . Three
hours following treatm ent, the to tal cell lysate was prepared, and 50 /A of the lysate
was added to 100 fil of reaction buffer (1 mM NADPH, 100 mM Na 2 H P 0 4 , 100 units
GSH reductase, and 1 mM DTNB). This m ixture was incubated for five minutes
at room tem perature (Baker et al., 1990). Absorbance was measured at 412 nm in
a 96-well m icrotiter plate using Bio-tek ELX 808ru U ltra M icroplate reader.

The

am ount of reduced glutathione was expressed per microgram of measured protein.
Three sets of experiments were done and three sets of measurements were taken for
each experiment. Averages were calculated from the results in each trial, and the
percentage error between each set of experiments was calculated.

3.2.5

M easurem ent of Total R eactive O xygen Species (ROS)

Detection of ROS production was monitered using the membrane permeable dye
2’,7’-dichlorofluorescein diacetate (DCFDA) (Siraki et al., 2002). M easurement of
total ROS production was measured after 3 hours of treatm ent w ith 100 fiM H 2 0

2

in control and transfected SH-SY5Y cells. DCFDA was added to the cell media to
a final concentration of 10 fiM, and incubated for 10 minutes a t 37°C. Cell lysate
was collected, and the pellet was resuspended in 1 X PBS, pH 7.4. Fluorescence
was measured using a Spectra Max Gemini XS multi-well plate fluorescence reader at
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an excitation wavelenth of 500 nm, and an emission wavelength of 520 nm. Protein
estim ation was measured using the Bradford reagent at an absorbance of 595 nm.
Results were expressed as a measurement of fluorescence units per microgram of
protein. Three sets of experiments were done and three sets of measurements were
taken for each experiment. Averages were calculated from the results in each trial,
and the percentage error between each set of experiments were calculated.
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3.3

R esults

3.3.1

O xidative and H ypoxia M easurem ents in U ndifferenti
ated SH -SY 5Y Cells

Control cells and stable lines of undifferentiated SH-SY5Y cells expressing both
G FP and PD L G FP were subjected to treatm ent with 100 fiM. H 2 O 2 , for one hour.
Following three hours, the cells were stained with Hoechst (to examine nuclear mor
phology) and M itotracker (to examine mitochondrial membrane potential) dyes to
access the morphological characteristics of apoptosis (figure 3.1). Cells were exam
ined under a fluorescent microscope at a magnification of 400 x. For both lines of
control cells, the characteristic of nuclear condensation (blue cells) was shown in fig
ure 3. IB and 3. IE by the rounding up, and clumping of cells. Figure 3.1H contains
the PD L G FP cells, showing a reduction in nuclear condensation and cell clumping.
The arrow indicates the single apoptotic nucleus found in th a t frame. A loss of mi
tochondrial membrane potential of both lines of control cells was observed through
the diffusion of the red stain in figure 3.1C and 3.IF . In figure 3.11 containing the
PD L G FP cell line, the presence of more pronounced, stained m itochondria indicates
the maintenance of membrane potential. M aintenance of mitochondrial membrane
potential was observed in greater than 75% of the observed P D L G FP containing cells.
Following cellular staining, the total cell lysate of each cell line was collected,
and DCFDA, a fluorescent probe which measures the am ount of ROS, was added
to the lysate. A measurement of the to tal fluorescence expressed per microgram of
protein was quantified (figure 3.2). These experiments were repeated three times, and
measurements were taken three times for each trial. Green columns represent ROS
measurements in untreated cells, and violet columns represent ROS measurements
cells exposed to oxidative stress. In the PD L G FP cells, there is a reduced production
of ROS as compared to the control lines.

On average ROS levels increase by 16

fluorescence units per microgram protein in the control cells, whereas they increased
only by 5 fluorescence units per microgram protein in the P D L G FP cells. In parallel,
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the number of micromoles of reduced glutathione produced per microgram of protein
was measured in treated and untreated cells.

Detection w ith DTNB determined

the number of reduced thiols for undifferentiated cells treated w ith H 2 O 2 . Three
separate experiments were done measuring the number of reduced thiols, and three
measurements were taken for each trial.

Green panels in figure 3.3 represent the

glutathione measurements in untreated cells, and violet panels represent glutathione
measurements in cells exposed to oxidative stress. Figure 3.3 dem onstrates a large
reduction in the am ount of GSH, an average of 2.5 pm ol//rg of protein, in both control
lines after exposure to oxidative stress. There is a smaller reduction in GSH levels of
0.4 pmol//xg of protein in cells expressing PDLGFP.
Undifferentiated transiently transfected G FP and PD L G FP cells were treated with
100 jjM H 2 O 2 , for one hour. Following three hours, the cells were stained with Annexin V dye to observe membrane flipping of phosphatidylserine, which is indicative
of the early stages of apoptosis. Once the dye is bound to phosphatidylserine on
the outer leaflet, a visible orange colour outling the membrane is present. Cells were
examined under a fluorescent microscope at a magnification of 400 x. In figure 3.4A,
cells are untreated and there are no G FP expressing cells, and no cells th a t take up
the annexin V dye. In figure 3.4D and 3.4G, untreated cells show the presence of
GFP, and P D L G FP cells, respectively. In both D and G panels, no annexin binding
is present as expected in untreated cells. In the transiently transfected G FP cells,
figure 3.4E shows only the annexin V binding dye, and figure 3.4F shows the identical
field of view w ith G FP expressing cells. It is observed th a t the G FP only cells take
up the annexin V binding dye indicating phosphatidylserine membrane flipping. In
the transiently transfected PD L G FP cells, figure 3.4H show cells th a t take up the
annexin V binding dye. In figure 3.41, the identical field of view shows the pres
ence of P D L G FP expressing cells th a t did not take up the annexin V stain. Hence,
SH-SY5Y cells containing PD L G FP seem to evade early apoptotic cellular reponses
during hypoxic stress.
Undifferentiated control and stably transfected lines of SH-SY5Y were subjected to
hypoxic stress for six hours in a hypoxia chamber. All three cell lines were counted in
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three different fields of view, at 0, 4, 6 , 12, 24, and 48 hours following treatm ent. After
48 hours, all control lines were non-viable, whereas the P D L G FP cell line still had
approxim ately 20% of viable cells (figure 3.5). Therefore, the presence of PD LG FP
in SH-SY5Y cells delays apoptosis caused by hypoxic stress.

3.3.2

Inducing O xidative Stress in D ifferentiated SH -SY 5Y
C ells

Control SH-SY5Y cells, and a stable line of PD L G FP cells were differentiated
over 14 days. Figures 3.6A and 3.6B show phase contrast pictures of the morphology
of differentiated control cells before treatm ent with hydrogen peroxide. The elonga
tion of the cell body, and the neurite growth can be seen between the cells. Figure
3.7 shows the side by side comparison of phase contrast and fluorescence micrscopy
pictures of differentiated PD LG FP cells before treatm ent w ith hydrogen peroxide.
Cell body elongation, and neurite growth can be seen in the P D L G FP cells, with the
presence of the recombinant PD LG FP throughout.
Following differentiation, cells were treated w ith 100 m uM H 2 O 2 , for one hour.
After three hours cells were stained with Hoechst and M itotracker dyes to examine the
cells for the apoptotic features of nuclear condensation and m itochondrial membrane
potential. Cells were examined under phase contrast and fluorescent microscopy at
400 x magnification. Figures 3.8 and 3.9 are two examples of the comparison of treated
control and PD L G FP cells. All of the nuclei of the control cells were condensed and
rounded, indicative of nuclear condensation during cell death in figures 3.8E and 3.9E,
whereas most of the nuclei in PD LG FP cells maintained normal morphology as in
dicated by th e absence of cell rounding, and clumping (figure 3.8F and 3.9F). The
blurry red colour seen in figures 3.8C and 3.9C of the control cells indicate a loss of
mitochondrial membrane potential. The mitochondrial membrane potential of most
PD LG FP cells remained intact as exhibited by the defined red colour in figures 3.8D
and 3.9D. Figure 3.10 shows more phase contrast and fluorescent microscopy pictures
of additional PD L G FP cells after treatm ent; figures 3.10B and 3.10 D show th a t
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nuclear morphology is intact, figures 3.10B and 3.10D indicate th a t mitochondrial
membrane potential is preserved. These photographs further support th a t the pres
ence of PD L G FP in differentiated SH-SY5Y cells protects against apoptosis induced
by oxidative stress.
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3.4

D iscu ssio n
Many studies of apoptosis often work towards application for neurodegenerative

diseases and stroke. To gather further evidence for PD I as a neuroprotective protein,
SH-SY5Y neuroblastom a cells were chosen as an appropriate model. In working with
these cells, difficulties arose in th a t their number of divisions was very limited and
finite. It was im portant to generate lines of stable cells, and perform experiments
before cells reached senescence, which usually occurred between divisions

10

and

11.

Also, because of this obstacle for every set of experiments undertaken, new stable
cell lines had to be generated, and no stocks of cells could be made. This created a
quandary in th a t the characteristics of each new cell line generated may have varied.
C haracteristics aside, the assumption was made th a t PDI function w ithin the cell
should rem ain th e same.

3.4.1

S tab le S H -S Y 5Y Cells E xpressing P D IrG F P are P ro
tectiv e A gainst O xidative Stress

Reactive oxygen species in the cell include superoxide, peroxynitrite, and the hy
droxy radical. Oxidative stress has been shown to induce apoptosis in systems such
as muscle and neuronal cells (Kroemer et al., 1997). Oxidative stress was induced
artificially in the cells with hydrogen peroxide treatm ent. Although not understood,
cell death by ROS has been hypothesized to lead to mitochondrial dysfunction with
the release of cytochrome C and apoptosis initiating factor, which then activates a
caspase pathway (Strasser et al., 2000). Alternatively, ROS could cause DNA dam
age, and lead to a p53/B ax pathway inducing apoptosis (Li et al., 1999). A recent
paper by Chun and coworkers in 2001, proposed th a t ROS induced JNK1/2-M APK,
followed by cJun phosphorylation, and the expression of cell death genes. If ROS
induces cell stress through the JNK 1/2-M A PK pathway, then expression of the CMV
IE prom oter may have been upregulated, and in doing so, upregulated the expression
of the recom binant PDLGFP. This appears to be evident in the results, in th a t in
ducing stress w ith ROS preserved nuclear morphology and m itochondrial membrane
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potential in those cells containing PDLGFP, whereas cell death was marked in un
transfected cells, and transfected cells expressing G FP only. M easurement of ROS
produced by the cells after oxidative stress was measured, and showed an average
increase of 15 fluorescence units per microgram of protein in both lines of control
cells, whereas th e average increase in cells expressing the P D L G FP protein was only
6

fluorescence units per microgram of protein, almost a 3-fold decrease. Clearly, intro

ducing an excess of PD I into SH-SY5Y cells shows to delay the apoptotic mechanism
in evading cell death. Phosphatidylserine flipping, an early apoptotic event was de
tected using Annexin V dye on transiently transfected cells. Annexin V only binds to
phosphatidylserine exposed on the cell surface when it flips from the inner to outer
leaflet of the cytoplasmic membrane.

3.4.2

S tab le SH -SY 5Y Cells E xpressing P D IrG F P M aintain
th e R ed ox B alance

Redox balance throughout the cell is m aintained by the relative concentrations
of GSH:GSSG. The cytoplasm of the cell is generally a very reducing environment,
with concentrations of GSH:GSSG residing around 30:1 - 100:1 (Raina and Missiakas, 1997). Under oxidative stress, the environment in the cytoplasm becomes more
oxidative and the concentration of GSH decreases, as it is oxidized to GSSG. GSH
levels were measured using 5,5’-dithio-6is- (2-nitrobenzoic acid), or DTNB which re
acts w ith free sulfydryl groups resulting in the formation of 2-nitro-5-thiobenzoic acid
(TNB) and a mixed disulfide (Riener et al., 2002). The average decrease in GSH levels
in both lines of control cells under oxidative stress was 2.5 picomoles per microgram
of protein, whereas the average decrease in cells expressing PD L G FP was only 0.4
picomoles per microgram of protein. This dem onstrates th a t PD I works to m aintain
the reducing environment within the cells under stress.
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3.4.3

Stable SH -SY 5Y Cells E xpressing P D L G F P D elay A pop 
tosis

Isch em ia , a c o n d itio n cau sed b y lack o f o x y g en to cells ca n resu lt in m assive

cell death, especially in brain stroke. It has been dem onstrated th a t PDI expression
is elevated only in the cerebral cortex of rats with brain ischemia, but not in the
hippocampus, cerebellum, or other areas (Tanaka et al, 2000). The number of viable
cells remaining in control lines and PD LG FP lines were assessed over a 48 hour
period after ischemic stress. By 48 hours all of the control cells had died, whereas
the P D L G FP cell line still had an average of 20% of viable cells remaining. This
observation again exhibits the neuroprotective effect PDI has in SH-SY5Y cells.

3.4.4

D ifferentiated Stable SH -SY 5Y Cells E xpressing P D L G F P
P ro tect C ells from ROS

Control and stable cell lines were differentiated not only to localize PD LG FP
within SH-SY5Y cells, b u t also to examine the presence of nuclear morphology and
mitochondrial membrane potential associated with apoptosis following hydrogen per
oxide treatm ent. Over the course of 14 days of treatm ent and cell differentiation,
many cells died in all lines; the stable G FP cell lines did not remain viable, and
most had died off by the ten th day. A possible reason for the complication could be
the presence of G418 in the serum deprived media containing only BDNF. G418 is a
selective antibiotic which can only be metabolized by the enzyme neomycin phospho
transferase, whose gene is found in the pE G F P -N l plasmid. The presence of G418 in
the media keeps the plasmid inside the SH-SY5Y cells. Any cells th a t do not contain
the plasmid, are killed by the toxic antibiotic, as they do not contain the gene to
metabolize it. The high copy number of the plasmid also allowed for a high number
of plasmid replication. Excess PDI in the PD L G FP strain may have contributed to
the maintenance of the cell line during differentiation. Pictures comparing the control
and PD L G FP line after differentiation show a decreased level of neurite growth in
the P D L G FP line, and a decreased number of neurite contacts made, as compared to
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the control cells. Again, this may be due to the presence of G418 within the media,
which may somehow hinder the growth and formation of differentiated cells. Upon
treating the cells w ith hydrogen peroxide, these studies dem onstrate definitively th a t
the P D L G FP cell line does protect the cells from oxidative stress to an extent. Cell
death appears to be slowed down in the PD L G FP cells as compared to the control
cells, although initial characteristics of apoptosis begin to appear w ith the beading
of neurites as illustrated in figures 3.8F and 3.9F.
In summary, additional evidence was gathered to support th a t PD I works as a
neuroprotective protein in response to oxidative and ischemic stress. PD L G FP cells
m aintained nuclear morphology, and mitochondrial membrane potential during ox
idative stress. These cells showed a much lesser increase in th e level of ROS produced
as compared to the control cells. Reduced glutathione levels in the PD L G FP cells
were closer to untreated levels after oxidative stress than th e control cell lines. These
effects may be contributed to the upregulation of another protein - ubiquilin, which
has been shown to associated with PD I during stress induced cell death (Ko et al.,
2002). A marked reduction in the apoptosis of PD L G FP cells may also be attributed
to its anti-chaperone activity within the cell (Quan et al, 1995, Goldberg et al., 1991,
Walker and G ilbert, 1997). PD I can act as an anti-chaperone to aggregate unfolded
proteins w ithin the endoplasmic reticulum to help protect them from protein degration.
Previous studies have also proposed th a t ROS may be involved w ith the activation
of NF-kB (Li et a l, 1999). A recent study proposed th a t PD I suppresses NF-AB activ
ity (Higuchi et a l, 2004). This may also in some way contribute to cell death protec
tion. This localization of SH-SY5Y cells using recombinant P D L G FP dem onstrated
th a t this protein was found throughout SH-SY5Y cells. Lahav and coworkers (2000)
identified PD I at the cell surface of blood platelets m ediating integrin-dependent ad
hesion, although it was not stated how many disulfide bonds are oxidized or reduced
in the integrins. During apoptosis, cells begin to detach from each other and from
their m atrix. The ability of PD I to delay cell death may also be dependent on its
ability to prom ote disulfide exchange in integrin adhesion.
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More research needs to be conducted on the ability of PD I to protect cells from
death. Its protein-protein interactions, downstream signalling, and mechanism by
which it functions still needs to be elucidated. Once more is understood about PDI,
drugs th a t could further upregulate its expression may be useful in treating stroke
victims and other diseases marked by massive cell death.
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Figure 3.1: Morphology of control and stable SH-SY5Y cells following oxidative stress.
Undifferentiated SH-SY5Y cells were treated with 100 /jM hydrogen peroxide. Fol
lowing three hours, cells were examined for the presence of morphological features of
apoptosis including cell lifting, nuclear condensation, and m itochondrial membrane
potential.

Frames A, B, and C show the phase contrast, Hoechst stain, and Mi

totracker stain respectively, of the untransfected control cells. Frames D, E, and F
show the phase contrast, Hoechst stain, and M itotracker stain of th e G FP transfected
control cells. Frames G, H, and I show the phase contrast, Hoechst stain, and Mi
totracker stain of the PD L G FP transfected cells. The arrow in Frame H points to
a condensed nucleus found within the PD LG FP field of view. All photographs were
taken at 400 x magnification.
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ROS Produced by SH-SY5Y Cells After Oxidative
Stress
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Figure 3.2: Production of reactive oxygen species in control and stable SH-SY5Y
cells. Undifferentiated SH-SY5Y cells were treated with 100 fiM hydrogen peroxide.
After three hours, cell lysate was collected and 2’,7’-dihydrofluorescein (DCFDA) flu
orescent dye was added to the lysate. M easurements of the reactive oxygen species in
both treated and untreated cells were taken, and expressed as the number of fluorescnet units per microgram of protein. The first two bars represent the untransfected
control cells, the second set represent the stable cells expressing only GFP, and the
third set represent the stable cells expressing PDLGFP. Error bars are based on the
standard error between sets of experiments.
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GSH M easurement in SH-SYSY C ells After Oxidative
Stress
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Figure 3.3: M easurement of GSH levels after oxidative stress in control and stable
SH-SY5Y cells. Undifferentiated SH-SY5Y cells were treated w ith 100 fiM hydrogen
peroxide. Following three hours, cell lysate was collected and incubated with the
reaction buffer as described in the m ethods section. GSH levels in bo th treated and
untreated cells were measured and expressed per microgram of protein. The first two
bars represent th e untransfected control cells, the second set represents the stable
cells expressing only GFP, and the third set represents the stable cells expressing
PD hG FP. Error bars are based on the standard error between sets of experiments.
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Figure 3.4: M embrane flipping of control and transiently transfected SH-SY5Y cells
after oxidative stress.

Undifferentiated SH-SY5Y cells were treated w ith 100 fjM

hydrogen peroxide. Following three hours, cells were examined for the phosphatidyl
serine flipping using Annexin V dye. Frame A shows the untreated control cells, frame
B and C show the treated control cells (the same frame is used to show the absence
of G FP cells w ithin the control line). Frame D shows untreated G FP cells, frame
E displays treated G FP cells, and frame F displays the same field of view as E, but
showing both G FP and annexin V binding. Frame G displays untreated PDLGFP,
frame H displays treated PD L G FP cells, and frame I displays the same field of view
as H, b u t showing both PD L G FP cells in the presence of annexin V binding. All
photographs were taken at 400 x magnification, under fluorescent microscopy.
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Effects of Ischemia on Stable SH-SY5Y Cells
Expressing PDI:GFP
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Figure 3.5: Assessment of cell viability following ischemic stress. Undifferentiated
control and stable SH-SY5Y lines were subjected to ischemia for

6

hours. Cells were

examined using phase contrast microscopy, and three different areas were counted for
the number of viable cells following stress induction at time periods of 0, 4, 6 , 12, 24,
and 48 hours. Results were expressed as a percentage of viable cells remaining. Error
bars are based on the standard error between sets of experiments.
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Figure 3.6: Differentiated SH-SY5Y cells before oxidative stress. Cells were differen
tiated for 14 days as described in the m ethods section. Phase contrast photographs
were taken of th e cells prior to inducing oxidative stress, to examine for morpholog
ical features of differentiated cells which include, cell body elongation, and neurite
lengthening and contact. Frames A and B show two different fields of view of the
differentiated control cells. All pictures were taken at 400 x magnification under a
phase contrast microscope.
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Figure 3.7: Differentiated PD LG FP SH-SY5Y cells before oxidative stress.

Cells

were differentiated for 14 days as described in the methods section. Photographs
of the cells were taken prior to inducing oxidative stress, to examine morphological
features of differentiated cells. Frames A and C show two different fields of view of
the differentiated PD L G FP cells under phase contrast microscopy. Frames B and
D show the same frames as A and C, under fluorescent microscopy. Cells in frames
B and D were examined for the presence of the recom binant P D L G FP protein. All
pictures were taken at 400 x magnification.
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Figure 3.8: Morphology of control and stable differentiated SH-SY5Y cells after oxida
tive stress. Differentiated SH-SY5Y cells were treated with 100 /iM hydrogen perox
ide. Following three hours, cells were examined for the presence of the morphological
features of apoptosis including cell lifting, nuclear condensation, and mitochondrial
membrane potential. Frames A, C, and E show the phase contrast, Hoechst stain,
and M itotracker stain respectively, of the control cells. Frames B, D, and F show
the phase contrast, Hoechst stain, and M itotracker stain of the PD IrG FP cells. All
photographs were taken at 400 x magnification. Frames A and B were taken under
phase contrast microscopy, and frames C, D, E, and F were taken under fluorescent
microscopy.

77

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Control
Untransfeeted, Treated

PDLGFP
Transfected, Treated

Phase Contrast

Mitotracker stain

F

Hoechst

Figure 3.9: Morphology of control and stable differentiated SH-SY5Y cells after ox
idative stress. Following three hours, cells were examined for the presence of the
morphological features of apoptosis including cell lifting, nuclear condensation, and
mitochondrial membrane potential. Frames A, C, and E show the phase contrast,
Hoechst stain, and M itotracker stain respectively, of the control cells. Frames B, D,
and F show the phase contrast, Hoechst stain, and M itotracker stain of the PD LG FP
cells. All photographs were taken at 400 x magnification. Frames A and B were
taken under phase contrast microscopy, and frames C, D, E, and F were taken under
fluorescent microscopy.
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Figure 3.10: Morphology of differentiated PD L G FP cells following oxidative stress.
Differentiated P D L G FP cells were examined for the presence of the morphological
features of apoptosis. Frame A shows cells under phase contrast microscopy, frame B
shows cells stained w ith Mitotracker, frame C shows P D L G FP protein and Hoechst
stained nuclei, and frame D shows cells stained w ith both M itotracker and Hoechst.
All photographs were taken at 400 x magnification. Frame A was taken under phase
contrast microscopy, and frames B, C, and D were taken under fluorescent microscopy.
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Chapter 4
D irections for Future Study
In further studies of PD I as a neuroprotective protein, it is im portant to deter
mine how it interacts w ith other molecules w ithin the cell. During ischemic stress,
inducible NO synthase is upregulated which generates excess am ounts of nitric oxide
(Moriya et al., 2000). Moriya and coworkers also dem onstrated th a t excess NO causes
apoptosis through the initial loss in mitochondrial membrane potential and final
downstream caspase signalling resulting in DNA degradation. It has been suggested
th a t PD I is involved w ith the transport of intracellular NO equivalents (Sliskovic et al.,
2005). Future work could include the study of the addition of PD L G FP to SH-SY5Y
cells, and on th e determ ination of the intracellular NO levels when cells are exposed
to ischemic stress. PD I denitrosation activity can easily be monitored w ith the highly
fluorescent and sensitive probe, A-dansyl-S-nitrosohomocysteine (DAN), th a t reacts
with NOs , to form napthotriazole (NAT), which em its a fluorescent signal at 406 nm
(R aturi and M utus, 2004). By using this probe on the cell lysates of PD L G FP cells
exposed to ischemic stress, PDI denitrosation activity can be monitered.
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A p p en d ix A
T h e P D I seq u en ce u sed th ro u g h o u t th is th e sis w as o b ta in ed from th e
P D I c D N A clo n ed in to th e pE T -1 l a v ecto r, and seq u en ced a t th e W ayne
S ta te seq u en cin g facility. C onversion o f th e D N A to p ro tein seq u en ce was
done u sin g th e E x P A S y p ro teo m ic to o l from www.expasy.org.
1
10
20
D A P E E E D H V L V L R K S N F A E A L A A H K Y
JO
40
50
L LV E F Y A P f C f l H C K A L A P E Y A K A A G K
60
70
L K A E O S E I R L A K V D A T E E . S D L A Q Q Y G V
80
90
100
R G Y P T I K F F R N O D I A S P K E Y T A O R E A D
110
120
130
D I V N W L K K R T G P A A T T L P D G A A A E S L
140
150
160
V E S S E V A V I G F F K D V E S D S A K Q F L Q A A
170
180
E A I D D I ' P F G I T S X S D V F S K Y Q L D K D G V
190
200
210
V L F K K F D E X R N N F E G E V T K G E P A G L Y
220
230
240
0 TQPA A P C H R V P E Q T A P K I F 0 G X I K T H
250
260
I L L F L P F L P K S V S D Y D G K L S N F K T A A E S
270
280
290
F K G K I L F I F I D S D I T D N Q R I L E F F G L K K
300
310
320
E E C P A Y E L I T L E E E M 1 K Y K P E S E E L T A
330
340
350
E R I T E F C H R F L E G K I R P H L M S Q E L P E C
360
370
W D K . Q P V K V L V G K N F E D V A F D E K K N V F
380
390
400
V EFYAPW C GHCKQLAPIWDK.LGETYK.
410
420
D H E N I V I A K M D S T A . N E V E A V KV HS FP T
430
440
450
L K F F P A S A D R T V I D Y N ' G E R T L D G F K K F
460
470
480
L E S G G Q D G A G D D D D L E D L E E A E E P D M
490
E E I) D D 0 K A V K D E L
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A p p en d ix B
p E T -2 8 b vecto r from N ovagen www.novagen.com
m ® um
Not l(i»)
Sal kim
S o ejtm )
EedRfttsa)
B a tw H I p a s)

S p o t 102
Dra lfigH27)

Nhe 1(231)
Nde 1(258)

Noo Ha*)
Xba 1(338)
Bgl 11(401)
-* S p A 1(442)

" N ^ S p h If88»1

Pvul(442»»

Sma

V ^y M k l 1(1123)

^
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Niu l<Me$

y^BeUpm)
1 ',EWE IMso»)
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(m m p y

o* I i
i

J M p a 1(1334)

&t ;j1

^

#(1534)

/

‘EwRVftSW)
x Hpi

Emm I
AtwN 1(3640*

PshAI(lW8|

B «S kimn
B sp lU H 1(3224) <
Sap
Ics
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B s m o r W_j / T TiM
n tam ti f
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-Bgl l(2 W)
_..
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P«p5 11(2230)
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H in d fll

PDI cDNA 1.5 Kb

EcoRl

pET 28b;PDI
6.9 Kb

lad
on
pET-28b:PDI construct

'in d lll

PDIa cDNA 0.38 Kb

EcoRl
K

on
pET-2Sb:PDIa construct
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pEGFP-Nl vector from Clontech www.clontech.com

HSVTK
poly,A

EcoRl
PDI cDNA 1.5 Kb

pEGFP-Nl:PDI
Kant//Neot

6.2 Kb

SV40

PDI:pEGFP-Nl construct
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A p p en d ix C
Below is th e FORTRAN 90 code to generate primers given an insert and vector
saved in FASTA form at under insert.txt and vector.txt respectively. Once the pro
gram is opened, answer the list of questions prom pted by the program. Restriction
enzymes are to be entered by nucleotide sequence instead of names. Once all of the
information has been inputted, the program will generate forward and reverse primers
in the 5’ to 3’ direction based on the information given.
PROGRAM primer
INTEGER amax, vmax, cmax, emax
PARAMETER (amax=2500, vmax=500, cmax=100, emax=10)
CHARACTER rdarray*(amax),rdrev*(amax)
CHARACTER insertfor*(cmax), insertmed*(cmax), insertrev*(cmax), &
vectorfor*(vmax), vectormed*(vmax), vectorrev*(vmax), &
enza*(emax), enzb*(emax),&
ou t 1 * (cmax),out2*(cmax)
INTEGER a , b , i ,j,k,ktot,nrd
INTEGER n c ,n g ,n t ,n a ,n i n s ,n v e c ,ntempf o r ,n t e m p r e v ,&
n e n z a ,n e n z b ,cut1,cut2,r f 1,rf 2,&
posl,pos2,pos3,nbuff,noutl,nout2,&
ocutl,ocut2
CHARACTER n * l ,choice*l,buff1*1,buff2*1
LOGICAL found
REAL tl,t2,t
REAL temperaturefor(cmax),temperaturerev(cmax)

w r i t e (*,*)’* -----------------------------------------w r i t e (*,*)’* I Primer Generator
writ;e(*,*)’* | By: R.A. Nistor and D. Seslija
w r i t e (*,*)’* | To be used under the GNU Licence.
w r i t e (*,*)’* -----------------------------------------w r i t e (*,*)’* I Comments?
Questions? ... :(
w r i t e (*,*)’* ------------------------------------------

*’
I*’
I*’
j*’
*’
|*’
*’

writ) ©(*,*)*******************************************’
w r i t e (*,*) >----------------------------------------------- ’
a=amax
open (unit=80, f i l e = ’insert.txt’, s tatus=)0 L D > )
read (unit=80,f m t = ’(A\a)’)rdarray
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call CAPITALIZE(rdarray,amax)
call CHECKARRAY(rdarray,amax)
nins=FINDSIZE(rdarray,amax)
call COUNTNUCS(rdarray,a m a x ,n i n s ,n c , n g ,n t ,n a ,ns)
write(*,fmt=’(A10,15,A 1 8 ) ’) ’Insert i s ’, n i n s , ’nucleotides long,
w r i t e (*,fmt=’(A9,I4,A3,I4,A3,I4,A3,I4,A19,I4,A8)’)&
’C o n t a i n s ’,nc,’C , ’,ng,’G , ’,nt,’T , ’,&
n a , ’A nucleotides, a n d ’,ns,’s paces.’
call A SSIGN(rdarray,c m a x ,insertfor)
call REVASSIGN(rdarray,n i n s ,cmax,insertmed)
call COMPLIMENT(insertmed,c m a x ,insertrev)
call BLANK(rdarray)
close (unit=80)
w r i t e (*,*) ’----------------------------------------------- ’
open(unit=81, f i l e = ’vector.txt’, s tatus=’O L D ’ )
read (unit=81,fmt=’(A\a)’)rdarray
call CAPITALIZE(rdarray,amax)
call CHECKARRAY(rdarray,amax)
nvec=FINDSIZE(rdarray,amax)
call C O U N TNUCS(r d a r r a y ,a m a x ,n v e c ,n c ,n g ,n t ,n a ,n s )
write(*,fmt=’(A10,14,A 1 8 ) ’) ’Vector i s ’, n v e c , ’ nucleotides long
write(*,fmt=’(A9,I3,A3,I3,A3,I3,A3,I3,A19,I3,A8)’)&
’C o n t a i n s ’,nc,’C , ’,ng,’G , ’,nt,’T , ’,&
n a , ’A nucleotides, a n d ’,ns,’spaces.’
call ASSIGN(rdarray,v m a x ,vectorfor)
call REVASSIGN(rdarray,n v e c ,v m a x ,vectormed)
call COMPLIMENT(vectormed,v m a x ,vectorrev)
call BLANK(rdarray)
close (unit=81)
!w r i t e (*,*)insertfor(1:cmax)
!w r i t e (*,*)insertrev(1:cmax)
!write(*,*)vectorfor(l:nvec)
!write(*,*)vectorrev(l:nvec)
!stop
write(*,*) ’----------------------------------------------- ’
100 continue
w r i t e (*,*)’Please enter a Temperature range (in C e l . ) ’
w r i t e (*,f m t = ’(\A10)’) ’ Initial: ’
read.(*,*)tl
w r i t e (*,f m t = ’(\A10)’) ’
Final: ’
read.(*,*)t2
write(*,fmt=’(A21,F6.1 ,A3,F6.1,A10)’) ’Temperature range = ’,&
t l , ’t o ’,t2,’ deg. C e l . ’
w r i t e (*,*) ’----------------------------------------------- ’
nc=0; ng=0; nt=0; na=0; ns=0;
found=.false,
do 20 i=l,cmax
if ( insertfor(i:i).eq.’C ’
if ( insertfor(i:i ) .eq.’G ’
if ( i n s ertfor(i:i ) .eq.’T ’
if ( i n s ertfor(i:i ) .e q . ’A ’
t= T E M P ( n c ,n g ,n t ,na)
temperaturefor(i)=t
if ( t.ge.tl .AND. t.le.t2
foun d = . t r u e .
ntempfor=i

)
)
)
)

nc=nc+l
ng=ng+l
nt=nt+l
na=na+l

) then

99

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission

write( * , f m t = ’(A31,12,A4,F6.1 ,A11)’) ’For insert, found at position ’ , k
i , \ T = ’,t
goto 200
end if
if ( .NOT.found .AND. t.gt.t2 ) then
w r i t e (*,*)’ERROR: Temperature range is possibly too small for i nsert’
w r i t e (*,f m t = ’(A24,I3,A7,F6.1,A2,F6.1)’) ’For nucleotide p o s i t i o n ’,&
i , ’, T = ’,temperaturefor(i-1), ’- ’,t
w r i t e (*,*) ’----------------------------------------------- ’
goto 100
endif
if ( i.eq.cmax) then
w r i t e ( * , * ) ’ERROR:
Temperature range too h i g h ’
w r i t e (*,f m t = ’(A18,F6.1 ) ’) ’Max possible T = ’,t
w r i t e (*,*) ’----------------------------------------------- ’
goto 100
endif
20 continue
200 continue
nc=0; ng=0; nt=0; na=0; ns=0;
found=.false.
do 21 i=l,cmax
if ( insertrev(i:i ) .e q . ’C ’) nc=nc+l
if ( insertrev(i:i ) .e q . ’G ’) ng=ng+l
if ( insertrev(i:i ).eq.’T ’) nt=nt+l
if ( insertrev(i:i ) .e q . ’A ’) na=na+l
t = T E M P ( n c ,n g ,n t ,na)
t emperaturerev(i)=t
if ( t.ge.tl .AND. t.le.t2 ) then
found=.true.
ntemprev=i
w r i te(*,fmt=’(A42,I2,A4,F6.1,A11) ’)&
’For insert compliment, found at position ’,i,’, T = ’,t
goto 300
endif
if ( .NOT.found .AND. t.gt.t2 ) then
w r i t e (*,*)’ERROR: Temperature range is possibly too small for insert c omp.’
w r i t e ( * ,fmt=’(A24,I3,A7,F6.1,A2,F6.1 ) ’) ’For nucleotide p o s i t i o n ’,&
i , ’, T = ’,temperaturerev(i-l),
,t
write(*,*) ’----------------------------------------------- ’
goto 100
endif
if ( i.eq.cmax) then
w r i t e ( * , * ) ’ERROR:
Temperature range too h i g h ’
w r i t e (*,f m t = ’(A18,F6.1)’) ’Max possible T = ’,t
write(*,*) ’----------------------------------------------- ’
goto 100
endif
21 continue
300 continue
a=emax
w r i t e ( * ,*) ’----------------------------------------------- ’
writ;e(*,fmt=’(\A42)’) ’Please enter the 1st restriction enzyme:
read(*,fmt=’(A\a)’)enza

’

call CAPITALIZE(enza.emax)
call CHECKARRAY(enza,emax)
nenza=FINDSIZE(enza,emax)
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write(*,fmt=’(\A41)’) ’After what position is this enzyme cut:
read(*,*)cutl

’

w r i t e (*,fmt=’(\A42)’) ’Please enter the 2nd restriction enzyme:
read(*,fmt=’(A\a)’)enzb

’

call CAPITALIZE(enzb,emax)
c al1 C H E C KARRAY(e n z b ,emax)
nenzb=FINDSIZE(enzb,emax)
w r i t e (*,f m t = ’(\A41)’) ’After what position is this enzyme cut:
r e a d ( * ,*)cut2

’

if ( cutl.gt.nenza .OR. cut2.gt.nenzb) then
w r i t e (*,*)’ERROR: cut range beyond the size of the e n z y m e ’
goto 300
endif
w r i t e (*,*) ’----------------------------------------------- ’
write(*,fmt=’(\A25)’) ’1st restriction enzyme: ’
do 22 i=l,nenza
w rite( * , f m t = ’(\A1)’)enza(i:i)
if ( i.eq.cutl ) w r i t e (*,f m t = ’(\A1) ’) ’ | ’
22 continue
w r i t e (*,*)
write(*,fmt=’(\A25)’) ’2nd restriction enzyme: ’
do 23 i=l,nenzb
w r i t e (*,fmt=’(\A1)’)e n z b ( i :i)
if ( i.eq.cut2 ) w r i t e (*,f m t = ’(\A1)’) ’ |’
23 continue
write(*,*)
400 continue
write(*,fmt=’(\A51)’) ’Are you satisfied with these selections (y or n)?
read.(*,*) choice
if ( choice.eq.’y ’ ) then
goto 500
else if ( c h o ice.eq.’n ’ ) then
goto 300
else if (choice.ne.’y ’ .AND. choice.ne.’n ’) then
goto 400
endif
500 continue
w r i t e (*,*) ’----------------------------------------------- ’
posl=0
pos2=0
call F I N D E N Z (v e c t o r f o r ,vmax,nvec,enza,emax,nenza,posl)
call FINDENZ(vectorfor,v m a x ,n v e c ,e n z b ,e m a x ,n e n z b ,pos2)
call FINDENZ(vectorrev,v m a x ,n v e c ,e n z b ,e m a x ,n e n z b ,pos3)
if ( posl.eq.O ) then
w r i t e ( * ,*)’ERROR: 1st restriction enzyme not found in v e c t o r ’
goto 300
endif
if ( pos2.eq.O ) then
w r i t e ( * , * ) ’ERROR: 2nd restriction enzyme not found in v e c t o r ’
goto 300
endif
if ( posl.gt.pos2 ) then
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’

w r i te(*,*)’ERROR: 2nd restriction enzyme found before 1st . ’
600 continue
wr ite(*,fmt=’(\A29)’) ’Enter new enzymes (y or n)? ’
read(*,*)choice
if ( c h o i c e .e q . ’y ’ ) then
goto 300

else if ( choice.eq.’n’ ) then
Stop
else if ( c h o i ce.ne.’y ’ .AND. choice.ne.’n ’ ) then
goto 600
endif
endif
w rite(*,fmt=’(A10,A20,I3,A10)’)enz a (1:n e n z a ) ,’ occurs at p o s i t i o n ’,p o s l ,&
’in v e c t o r ’
w r i t e (*,f m t = ’(A10,A20,13,A 1 0 ) ’)e n z b (1:n e n z b ) ,’ occurs at p o s i t i o n ’,pos2,&
’in v e c t o r ’
write(*,fmt=’(A10,A20,I3,A21)’)enzb(l:nenzb),’ occurs at p o s i t i o n ’,pos3,&
’in vector compliment’
write(* ,*) ’----------------------------------------------- ’
if ( pos3.eq.O ) then
w r i t e (*,*)’ERROR: restriction enzyme not found in the compliment.’
w r i t e (*,*)’In the 5p -> 3p directions, the vector and compliment a r e : ’
write(*,*)vectorfor(l:nvec)
w r i t e (*,*)v e c t o r r e v (1:nvec)
do 28 i=l,nvec
if ( i-(i/10)*10.eq.0
) then
write( * , f m t = ’(\A)’) ’ I’

©lSG
w r ite(*,fmt=’(\A)’) ’.’
endif
28 continue
w r i t e (*,*)
stop
endif
call FINDRF(vectorfor,v m a x ,n v e c ,p o s 1,r f 1)
call FINDRF(vectorrev,v m a x ,n v e c ,p o s 3 ,rf2)
nbuffl=rf1+2
nbuff2=rf2+2
write(*,fmt=’(\A57)’) ’Please enter the 1st buffer nucleotide (c, g, t, or a ) : ’
r e a d ( * ,*)buff1
call CAPITALIZE(buff1,1)
call CHECKARRAY(buff1,1)
write(*,fmt=’(\A57)’) ’Please enter the 2nd buffer nucleotide (c, g, t, or a ) : ’
read(*,*)buff2
call CAPITALIZE(buff2,1)
call CHECKARRAY(buff2,1)
do 30 j=l,nbuffl
o u t l ( j :j)=buff1
30 continue
j=nbuff1+1
do 31 i=l,nenza
if ( e n z a ( i :i ) . n e .’ ’ ) then
if ( i.eq.cutl ) ocutl=j
o u t l ( j :j)=enza(i:i)

31 continue
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o u t l ( j :j) = ’A ’
out l (j + 1 :j+l) = ’T ’
outl(j+2:j+2)=’G ’
j=j+3
do 32 i=l,ntempfor
if ( insertfor(i:i ) . n e .’ ’ ) then
o u t l (j :j )=insertfor(i:i)
j=j + l
endif
32 continue
noutl=FINDSIZE(outl,cmax)
do 33 j=l,nbuff2
o u t 2 ( j :j)=buff2
33 continue
j=nbuff2+1
do 34 i=l,nenzb
if ( e n z b ( i :i ) . n e . ’ ’ ) then
if ( i.eq.cut2 ) ocut2=j
o u t 2 ( j :j ) = e n z b ( i :i)
j=j+1
endif
34 continue
do 35 i=l,ntemprev
if ( insertrev(i:i ) . n e .’ ’ ) then
o u t 2 ( j :j)=insertrev(i:i)
j=j+1
endif
35 continue
nout2=FINDSIZE(out2,cmax)
w r i t e (*,*) ’----------------------------------------------- ’
w r i t e (*,*)’Primers in the 5p -> 3p direction a r e : ’
w r i t e (*,*)
w r i t e (*,f m t = ’(A18,F6.1,\A3)’) ’Forward Primer (T=’,temperaturefor(ntempfor),’)
do 40 i=l,noutl
w r i t e (*,fmt=’(\A1)’)o u t l ( i :i)
if ( i.eq.ocutl ) write(*,fmt=’(\A1) ’) ’ I’
if ( i-(i/3)*3.eq.O ) w r i t e (*,f m t = ’(\A1)’) ’ ’
40 continue
w r i t e (*,*)
w r i t e (*,fmt=’(A18,F6.1,\ A 3 ) ’) ’Reverse Primer (T=’,temperaturerev(ntemprev),’)
do 41 i=l,nout2
wr i te(*,fmt=’(\A1)’)out2(i:i)
if ( i.eq.ocut2 ) w r i t e (*,fmt=’(\A1)’) ’ I’
if ( i-(i/3)*3.eq.O ) w r i t e (*,fmt=’(\A1)’) ’ ’
41 continue
w r i t e (*,*)
write(*,*) ’----------------------------------------------- ’
pause ’Press ENTER to c l o s e ’
End PROGRAM primer

J****************************************************************
!****************************************************************
subroutine FINDRF(vector,logicalsize,s i z e ,p o s ,r f )
INTEGER logicalsize,size,pos,rf
INTEGER i,j,s
CHARACTER vector*(logicalsize)
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s=0
do 10 i=l,pos
if ( v e c t o r ( i :i ) .e q . ’ ’ ) s=i
10 continue
rf=pos-s
end

su b ro u tin e

FIN D R F

subroutine F INDENZ(vector,logicalsize,s i z e ,s t r i n g ,l o g icaldim,d i m ,pos)
INTEGER l o g icalsize,s i z e ,logicaldim,d i m ,c u t ,r f ,pos
INTEGER i,j,k.match,space
CHARACTER vector*(logicalsize).string*(logicaldim)
do 10 i=l,size
match=0

100 continue
if ( vector(i+k:i+k).eq.string(j:j) ) then
match=match+l
if ( match.eq.dim ) then
pos=i
endif
if ( vector ( i + k + l :i+k+1).ne.’ ’ ) then
k=k+l
else
k=k+2
endif
if ( string(j+l:j+1).ne.' ’ ) then
j=j+l
else
j=j+2
match=match+l
endif
goto 100
endif
10 continue
end subroutine FINDENZ
subroutine COUNTNUCS(array,logicalsize,s i z e ,n c ,n g ,n t ,n a ,n s )
INTEGER i ,logicalsize,s i z e ,n c ,n g ,n t ,n a ,ns
CHARACTER array*(logicalsize)
nc=0; ng=0; nt=0; na=0; ns=0;
do 10 i=l,size
if (array(i:i).eq.’C ’)nc=nc+1
if (a r r a y ( i :i ) .e q . ’G ’)ng=ng+l
if (array(i:i ) .e q . ’T ’)nt=nt+l
if (array(i:i ) .e q . ’A ’)na=na+l
if (array(i:i ) .e q . ’ ’)ns=ns+l
10 continue
end subroutine COUNTNUCS
subroutine BLANK(rdarray)
INTEGER i.amax
PARAMETER (amax=2500)
CHARACTER rdarray*(amax)
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do 10 i=l,amax
r d a r r a y ( i :i) = ’ ’
10 continue
end subroutine BLANK
su b ro u tin e

C O M P L IM E N T (for, s i z e , r e v )

INTEGER i,j,k,size
CHARACTER f o r * (size),rev*(size)
LOGICAL first
do 10 i=l,size
if ( for(i:i).eq
if ( for(i:i).eq
if ( f o r ( i :i ) .eq
if ( f o r ( i :i ) .eq
if ( f or ( i :i ) .eq
10 continue

’C ’
’G ’
’T ’
’A ’
’ ’

)
)
)
)
)

r e v ( i :i) = *G *
rev(i:i)=’C ’
rev(i:i)=’A ’
r e v ( i :i ) = ’T ’
rev(i:i)=’ ’

end subroutine COMPLIMENT
subroutine ASSIGN(rdarray,s i z e ,array)
INTEGER i,amax,size
PARAMETER (amax=2500)
CHARACTER rdarray*(amax), array*(size)
do 10 i=l,size
a r r a y (i :i )=rdar r a y (i :i)
10 continue
end subroutine ASSIGN
subroutine REVASSIGN(rdarray,nrd,size,array)
INTEGER i ,amax,size,nrd
PARAMETER (amax=2500)
CHARACTER rdarray*(amax), array*(size)
do 10 i=l,size
a r r a y ( i:i)=rdarray(nrd-i+l:nrd-i+l)
10 continue
end subroutine REVASSIGN
subroutine CHECKARRAY(array,size)
INTEGER i ,size
CHARACTER array*(size)
do 10 i=l,size
if ( array(i:i).ne.’ ’ .AND. a rray(i:i ) . n e .’C ’ .AND. &
a r r a y ( i :i ) . n e .’G ’ .AND. a rray(i:i ) . n e .’T ’ .AND. &
a r r a y ( i :i ) . n e .’A ’ ) then
write(*,*)i,array(i:i),’ Unknown nucleotide d e t e c t e d . ’
stop;
endif
10 continue
end subroutine CHECKARRAY
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subroutine CAPITALIZE(array,size)
INTEGER i,size
CHARACTER array*(size)
do

10

i= l,s iz e

if ( a r r a y ( i :i ) .e q . ’c ’)
if ( a r r a y ( i :i ) .e q . ’g ’)
if ( array(i:i).eq.’t ’)
if ( a r r a y ( i :i ) .e q . ’a ’)
if ( array(i:i).eq.’ ’)
10 continue

array(i:i)=’C ’
a rray(i:i ) = ’G ’
a rray(i:i ) = ’T ’
array(i:i ) = ’A ’
array(i:i)=’ ’

end subroutine CAPITALIZE
]s|c3|c9(!e9|c3)(3|'$)|c9|c9|c»|e3{cj(c)|c9|c:tc»|c3|(;|c:tc3|c$3|c$>|c9|c9lc>|c3|c9ic$)|c9te:4c9|o|e>|o|e)|e9|c$)|c$$)|o|c:fc>|c:4c9|c)((:4c$)|c:4c:4()|o{c:4c)|c$$){c’l<

function TEMP(nc,ng,nt,na)
INTEGER nc,ng,nt,na
REAL t
t = 4 .0*(nc+ng)+ 2 . 0 * (nt+na)
TEMP=t
return
end function TEMP
function FINDSIZE(array.logicalsize)
INTEGER i,j,k,logicalsize.size
CHARACTER array*(logicalsize)
LOGICAL first,last
first=.false.
last=.false.
size=0
do 10 i=l.logicalsize
if ( a r r a y ( i :i ) . n e . ’ ’) first=.true.
if ( array(i:i).eq.’ ’ .AND. array(i+1:i + 1 ) .e q . ’ ’) last=.true.
if ( .NOT. last .AND. first) then
if ( array(i:i).eq.’C ’) size=size+l
if (array(i:i).eq.’G ’) size=size+l
if ( a r r a y ( i :i ) .e q . ’T ’) size=size+l
if ( a r r a y ( i :i ) .e q . ’A ’) size=size+l
if ( a r r a y ( i :i ) .e q . ’ ’) size=size+l
endif
10 continue
FINDSIZE=size
return
end function FINDSIZE
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